Introduction
============

Mutation or deletion of the survival motor neuron 1 (*SMN1*) gene in the presence of the *SMN2* gene results in an autosomal recessive neurodegenerative disorder, spinal muscular atrophy (SMA) ([@awz373-B31]). The *SMN1* and inverted copy *SMN2* are located on 5q13, the SMA locus. The two genes are similar, but differ by a critical single nucleotide in coding exon 7 that alters splicing and results in the majority of transcript from *SMN2* lacking exon 7 thus producing ∼90% of truncated protein SMNΔ7 and 10% of full-length SMN protein ([@awz373-B34]). SMA is caused by chronic low levels of SMN and is characterized by degeneration of the spinal cord motor neurons leading to muscle atrophy followed by respiratory failure and death ([@awz373-B3]).

The severity of SMA disease inversely correlates with the levels of SMN protein produced by varying numbers of *SMN2* copies present in affected individuals ([@awz373-B55]). Clinical reports show that SMA families with siblings that have homozygous *SMN1* deletion, identical *SMN2* copy number and inherited a haploidentical region of chromosome 5q13 display discordant phenotypes ([@awz373-B22]). These findings suggest that genes located outside of the 5q13 locus might be able to modify the SMA phenotype. Two classes of modifier genes may influence SMA phenotype: (i) SMN-independent and (ii) SMN-dependent modifiers. The SMN-independent modifier genes are those that do not influence SMN protein levels but their increased or reduced expression may modify SMA disease phenotype. The overexpression of plastin 3 (*PLS3*) and coronin 1C (*CORO1C*) genes, and the lack or reduction in expression of c-Jun NH~2~-terminal kinase 3 (*JNK3*), neurocalcin delta (*NCALD*) and calcineurin-like EF-hand protein 1 (*CHP1*) genes have been identified as SMN-independent modifiers that reduce disease severity and improve SMA phenotype ([@awz373-B40]; [@awz373-B19]; [@awz373-B24]; [@awz373-B44]; [@awz373-B25]). The SMN-dependent modifier genes have potential to modulate the levels of SMN by (i) increasing full-length SMN transcript by different mechanisms, including genes encoding (ii) transcription factors that alter expression of *SMN2* gene; (iii) splicing factors that enhance inclusion of exon 7; and (iv) proteins that may help stabilize protein-protein complexes and increase steady state levels of SMN protein ([@awz373-B4]; [@awz373-B2], [@awz373-B1]). The *SMN2* gene is the most characterized and viable modifier of SMA severity and an attractive target for identification of new SMN-dependent modifiers such as transcription and splicing factors that may increase full-length SMN transcripts and protein levels ([@awz373-B21]; [@awz373-B55]). However, the molecular mechanisms that regulate expression of *SMN* genes are largely unknown.

In this study, we investigated the function of zinc finger protein ZPR1 as a potential regulator of *SMN* gene expression. ZPR1 is essential for cell viability in yeast and mice but its biochemical function is unclear ([@awz373-B13]; [@awz373-B17], [@awz373-B16]). ZPR1 is present in the cytoplasm and the nucleus, and is required for accumulation of SMN in nuclear gems and Cajal bodies ([@awz373-B18], [@awz373-B16]). ZPR1 is a potential candidate modifier gene that is downregulated in SMA patients and may contribute to the severity of disease ([@awz373-B23]; [@awz373-B2]). However, whether ZPR1 overexpression will rescue SMA disease and emerge as a protective modifier of SMA remains to be examined. We investigated the effect of *in vivo* genetic overexpression of ZPR1 on the rescue of SMA using the SMAΔ7 mouse model ([@awz373-B30]). We also investigated the molecular mechanism of ZPR1-dependent prevention of R-loop and DNA damage accumulation and the rescue of SMA phenotype.

Materials and methods
=====================

Mice
----

### Creation of transgenic mice with ZPR1 overexpression (TFZP)

To create transgenic mice overexpressing ZPR1, *Flag-mZPR1* cDNA ([@awz373-B18]) was cloned into pBroad3 vector using AgeI/SmaI restriction sites downstream of the *Rosa26* promoter (InvivoGen) and vector was linearized by digestion with PacI. Transgenic mice expressing recombinant *Flag-mZPR1* gene under the control of the mouse *Rosa26* promoter (TFZP) were created on FVB/N genetic background by injection of linearized vector DNA into male pronucleus at the Transgenic Animal Modeling Core at the University of Massachusetts Medical School, Worcester, MA. Thirteen positive mice were detected in the F0 generation and bred for germline transmission. Four positive F1 lines (Lines 0, 1, 4 and 8) were positive for transgene cDNA. Lines 4 and 8 were found to express recombinant Flag-ZPR1 protein. Line 8 was characterized for copy number integration using genomic DNA and real-time quantitative PCR copy number assay (Applied Biosystems). Transgenic mice were genotyped for the presence of the *Flag-mZPR1* gene using PCR primers forward (5′-AGCGCCGAAGATGAGGAGCA-3′) and reverse (5′-ATCCAGCTCGGGGATCCTTG-3′).

### Generation of SMA mice with ZPR1 overexpression (Z-SMA)

SMA carrier mouse line (4299) (*Smn*^+/−^; *SMN2^+^*^/*+*^; *SMNΔ7^+^*^/*+*^) ([@awz373-B30]) on FVB/N background and wild-type FVB/N were purchased from the Jackson Laboratory and maintained in our laboratory. SMA carrier mice were crossed with TFZP (*Flag-Zpr1*^+/−^) mice on a pure FVB/N background and the first generations positive for the transgene were backcrossed three to four times to generate Z-SMA carrier mice with *Flag-Zpr1*^+/−^ (*Smn*^+/−^; *SMN2^+^*^/*+*^; *SMNΔ7^+^*^/*+*^; *Flag-Zpr1*^+/−^). Z-SMA carrier mice were bred to generate SMA (*Smn*^+/−^; *SMN2^+^*^/*+*^; *SMNΔ7^+^*^/*+*^) and Z-SMA (*Smn*^−/−^; *SMN2^+^*^/*+*^; *SMNΔ7^+^*^/*+*^; *Flag-Zpr1*^+/−^) littermates. The homozygous state of transgenes, *SMN2^+^*^/*+*^ and *SMNΔ7^+^*^/*+*^, was confirmed by breeding Z-SMA carrier mice with wild-type mice, and litters were examined by PCR ([@awz373-B30]) for the presence of *SMN2* and *SMNΔ*7 in all pups ([@awz373-B19]). Phenotypic analyses were blinded and littermates were genotyped for presence of *Flag-ZPR1* and gender after collection of data by PCR using tail DNA. Any combination of two or three pups with genotypes normal, SMA (*Smn*^−/−^; *SMN2^+^*^/*+*^; *SMNΔ7^+^*^/*+*^) and Z-SMA (*Smn*^−/−^; *SMN2^+^*^/*+*^; *SMNΔ7^+^*^/*+*^; *Flag-Zpr1*^+/−^) in a litter were considered littermates. All experiments and procedures were approved and performed according to the guidelines and policies set by the Institutional Biosafety Committee. All animals were housed in a facility accredited by the Association for Assessment and Accreditation of Laboratory Animal Care. All animal experiments were approved by the Institutional Animal Care and Use Committee of the Texas Tech University Health Sciences Center El Paso. Animals were treated and euthanasia was performed humanely using methods approved by the American Veterinary Medical Association.

Immunohistochemistry
--------------------

Mouse tissues, spinal cord and hind leg skeletal muscle from 7-day-old normal, SMA and Z-SMA littermates, were isolated, fixed in 4% paraformaldehyde (PFA) and processed for frozen sections as described previously ([@awz373-B19]). Thin serial sections (10 µm) were cut from the lumbar region of spinal cords and stained with haematoxylin and eosin or processed for immunohistochemical (IHC) staining. Motor neurons were counted in every fifth section (20 sections) of the lumbar (L1--L5) region of the spinal cord ([@awz373-B2]; [@awz373-B19]). For IHC staining, sections were processed for antigen retrieval, blocked in 3% bovine serum albumin (BSA) with 0.1% Triton™ X-100, incubated overnight with antibodies against SMN (610647, BD biosciences) and choline acetyl transferase (ChAT) (ab6168, Abcam) diluted (1:100) in 3% BSA. SMN was detected by using biotinylated secondary antibody, streptavidin-conjugated horseradish peroxidase and the substrate 3,3′-diaminobenzene followed by brief counterstaining with haematoxylin. ChAT was detected with secondary antibody coupled with Alexa 594-conjugated secondary antibody. Muscle sections (16 μm) from hind limb were blocked with 3% BSA with 0.1% Triton™ X-100 incubated with primary antibodies to β-actin (Sigma) and dystrophin (ab15277, Abcam) overnight. The next day, sections were washed, incubated with secondary antibody (Alexa 488) followed by washing with phosphate-buffered saline-Triton (PBST) (5 × 5 min). Double staining was performed using anti-neurofilament (NF-M, 145 kDa) (MAB1621, Millipore), anti-synaptophysin antibodies (ab14692, Abcam) and Alexa 594-conjugated α-bungarotoxin (BTX) for 60 min using sequential staining ([@awz373-B19]). Microscopic slides or coverslips were mounted using Vectashield with DAPI. Immunofluorescence was examined by confocal microscopy. Muscle fibre transverse sections stained with dystrophin were used to measure diameter of fibres. Fibre diameter was measured at three different points, including longest and shortest along the irregular circular shape of each fibre and averaged. One hundred fibres per mouse (three mice per group) were measured to determine myofibre diameter.

Primary spinal cord motor neuron culture
----------------------------------------

Mouse spinal cord explants from 7-day-old normal, SMA and Z-SMA mice were cultured *in vitro* for 12--14 days in 8-well chamber microscope slides, coated with poly-[d]{.smallcaps}-lysine/laminin using serum-free Neurobasal™ medium supplemented with B-27 ([@awz373-B19]; [@awz373-B27]). The identity and morphology of the spinal cord motor neurons and glial cells were established by staining with specific markers, including ChAT and Hlxb9 (Hb9) ([@awz373-B19]; [@awz373-B27]). Cultured neurons were infected with Ad5CMV-GFP or Ad5CMV-FlagZPR1-GFP (Viral Vector Core Facility, University of Iowa) at 100 MOI (multiplicity of infection) in a volume of 200 μl/well of 8-well chamber and 400 µl of medium added after 4 h and medium was replaced after 24 h. Neurons were either fixed (4% PFA) or harvested for protein extraction at 48 h post-infection for immunofluorescence and immunoblotting analysis, respectively.

SMA patient primary fibroblast and HeLa cell culture
----------------------------------------------------

Primary fibroblast derived from SMA type I patients, GM03813 and GM09677 were cultured in Dulbecco's modified Eagle medium (DMEM) supplemented with 15% foetal bovine serum (FBS) and HeLa cells were cultured in DMEM with 10% FBS ([@awz373-B18]; [@awz373-B27]). Cells were maintained at 37°C in a humidified atmosphere containing 5% CO~2~. Cells were cultured on glass coverslips (10^5^ cells**/**well) in 6-well plates and transfected with phrGFPIIc (GFP) or phrGFPIIc-FlagZPR1 (ZPR1-GFP) (1 µg**/**well) using Lipofectamine® 2000 according to the manufacturer's protocol ([@awz373-B18]; [@awz373-B27]). Cells were either harvested for immunoblot analysis or fixed for immunofluorescence analysis after 30 h post-transfection. Cells were also transfected with pcDNA3 or pcDNA3-FlagZPR1 and harvested after 30 h post transfection to isolate total RNA for analysis of SMN expression using real time PCR analysis ([@awz373-B18]; [@awz373-B27]). HeLa cells were mock-transfected (Control), transfected with antisense oligonucleotide against ZPR1 (As-ZPR1) and scrambled oligonucleotide (Scramble).

Immunoblot analysis
-------------------

Protein extracts for immunoblot analysis were prepared from mouse spinal cord, brain, heart, lung, liver and muscle tissues collected from 7-day-old normal, SMA and Z-SMA littermates, SMA patient cell lines GM03813 and GM09677 transfected with phrGFPIIc (GFP) or phrGFPIIc-FlagZPR1 (ZPR1-GFP), cultured primary spinal cord SMA neurons infected with adenovirus Ad5CMV-GFP (GFP) or Ad5CMV-FlagZPR1-GFP (ZPR1-GFP) ([@awz373-B27]) and HeLa cells co-transfected with human pGL3/SMN1-Luc or pGL3/SMN2-Luc with pcDNA3-FlagZPR1 or with antisense (As-ZPR1) and scramble (Scram) oligos ([@awz373-B20]). Cell and tissue lysates were prepared using Triton™ lysis buffer ([@awz373-B17]). Specific proteins were detected by automated capillary western blot system, Wes™ System (ProteinSimple), which uses capillary based electrophoretic separation and detection of proteins using antibodies as described previously ([@awz373-B27]). Signal intensity (area) of the protein was normalized to the peak area of loading control α-tubulin. The following primary phospho and non-phospho antibodies were used for immunoblot analysis, SMN (610647, BD Biosciences), ZPR1 (Clone LG-C61) ([@awz373-B20]), RNA Polymerase II (clone \#8WG16, BioLegend), recombinant Flag-ZPR1 was detected by Flag M2 (F1804, Sigma), γH2AX (phospho Ser 139) (ab26350), p-DNA-PKcs (Ser2056) (ab18192), total DNA-PKcs (ab53701), and senataxin (ab220827, Abcam), GFP (A11122, Invitrogen) and α-tubulin (T8203, Sigma). Data analysis and quantitation of protein levels were performed using Compass Software (ProteinSimple) ([@awz373-B27]). The relative levels of proteins \[mean ± standard error of the mean (SEM)\] normalized to tubulin, are presented.

Immunofluorescence analysis
---------------------------

Mammalian cells cultured on glass were washed with PBS and fixed in pre-chilled methanol (**−**20**°**C) for 5 min followed by 2 min in pre-chilled acetone at **−**20°C. Cell were stained with primary antibody against SMN, γH2AX, RNA-DNA hybrid (R-loops), 53BP1 or SETX for 1 h followed by secondary antibody Alexa 594-conjugated IgG (1 h) and coverslips were mounted on microscope slides with mounting medium containing DAPI ([@awz373-B18]; [@awz373-B27]). PFA fixed primary spinal cord motor neurons were washed with PBS, permeabilized with 0.1% Triton™ X-100 for 5 min, washed 3 × 5 min with PBS with 0.2% Tween-20 (PBS-T), blocked with 3% BSA in PBS-T for 30 min and double-labelled using sequential incubation (1 h each) with primary antibodies \[SMN, γH2AX, p-DNA-PKcs, RNA-DNA hybrid (R-loops) (S9.6) or SETX\] followed by secondary antibody Alexa 633-conjugated IgG, washed 3 × 5 min with PBS-T and incubated with second primary antibody, mouse anti-β-tubulin class-III neuron-specific antibody (clone TUJ1) or rabbit anti-tubulin β-III (TUBB3), washed 3 × 5min with PBS-T followed by incubation with Alexa 594-conjugated anti-mouse or anti-rabbit IgG secondary antibody ([@awz373-B27]). Immunofluorescence of stained cells was examined using a confocal microscope.

Real-time quantitative PCR analysis
-----------------------------------

Total RNA was isolated from (i) mouse spinal cord from 7-day-old normal, SMA and Z-SMA littermates; and (ii) SMA patient fibroblast cell lines, GM03813 and GM09677 transfected with pcDNA3 or pcDNA3-*FlagZPR1* using RNeasy® Mini Kit (Qiagen). Total RNA (100 ng) per sample was reverse-transcribed using SuperScript™ VILO cDNA synthesis Kit (Invitrogen). Real-time quantitative PCR (qPCR) amplification for full-length *SMN* and truncated *SMNΔ7* transcripts was performed using SYBR® Green Master Mix. Relative mRNA levels normalized to *GAPDH* were calculated using the 2^−ΔΔCT^ method ([@awz373-B33]; [@awz373-B20]; [@awz373-B27]). The primer sequences were as follows: mouse *Gapdh* primers: forward (5′-AAGGTCATCCCAGAGCTGAA-3′), reverse (5′-CTGCTTCACCACCTTCTTGA-3), human *GAPDH* primers: forward (5′-ATAGGCGAGATCCCTCCAA-3′), reverse (5′-TGAAGACGCCAGTGGAC-3′), *SMN2* Jxn E5/E6 forward F2 (5′-TTCCTTCTGGACCACCAATAA-3′), *SMN2* Jxn E7/E8 reverse R2 (5′-TCTATGCCAGCATTTCTCCTTAATTTAAG-3′) and *SMN2* Jxn E6/E8 Reverse R3 (5′-TGCTCTATGCCAGCATTTCCATAT-3′). Full-length *SMN* and *SMNΔ7* transcripts were amplified using F2+R2 and F2+R3 primers, respectively ([@awz373-B45]).

Chromatin immunoprecipitation-quantitative PCR assay
----------------------------------------------------

Chromatin samples were prepared from HeLa cells treated with 3.7% PFA to crosslink DNA and protein complexes. Chromatin was sheared by sonication to generate fragments ranging between 200 and 1000 bp. Chromatin immunoprecipitation (ChIP) was performed using antibodies against ZPR1 (Clone: LG-C61), H3K4me3 as a positive control and anti-Flag M2 as a negative control (IgG) according to manufacturer's protocol using Magna ChIP™ HiSens Kit. Real-time quantitative PCR amplification was performed using SYBR® Green reagents and human *SMN* promoter region, SMN1&2-F5: 5′-GATCTGCCGCCTTCCTTCCTG-3′, SMN1&2-R5: 5′-CTTAGGCCTCGTCTCGAACTC-3′ and SMN exon 1 region, SMN1&2-F3: 5′-CAGTGCAGTCTCCCTATTAGCG-3′ and SMN1&2-R3: 5′-CACAACTCCAGTGAGCGGATCG-3′. Levels of *SMN* genomic DNA present in ChIP with each antibody were measured using the comparative C~T~ (ΔΔC~T~) method for fold enrichment ([@awz373-B20]).

Effect of ZPR1 levels modulation on *SMN1* and *SMN2* gene expression
---------------------------------------------------------------------

To examine the effect of change in the levels of ZPR1 on alteration of the *SMN* gene expression, we used HeLa cells co-transfected with human *SMN1* or *SMN2* promoter driven luciferase reporter vector pGL3/SMN1-P750-Luc and SMN2-P750-Luc (provided by Dr Arthur Burghes) ([@awz373-B38]) and either pcDNA3-*FlagZPR1* (ZPR1 overexpression) ([@awz373-B2]) or with *ZPR1*-antisense oligonucleotides (As-ZPR1) (ZPR1 knockdown) ([@awz373-B15]). To examine the effect of ZPR1 knockdown, cultured HeLa cells were transfected with either human SMN-Luc or empty control reporter vectors (Con-Luc) using Lipofectamine® 2000. Transfected cells were retransfected after 24 h with scrambled or *ZPR1* antisense oligonucleotides to knockdown *ZPR1* levels. Cells were harvested after 24 h post second transfection for determination of luciferase activity or immunoblot analysis. To examine the effect of ZPR1 overexpression, HeLa cells were transfected with combinations of two plasmids: (i) Con-Luc + pcDNA3-*FlagZPR1*; (ii) SMN1-Luc + pcDNA3 (empty); (iii) SMN1-Luc + pcDNA3-*FlagZPR1*; (iv) SMN2-Luc + pcDNA3 (empty); and (v) SMN2-Luc + pcDNA3-*FlagZPR1* using the Lipofectamine® reagent. After 30 h post transfection, cells were harvested for determining luciferase activity or immunoblot analysis. Luciferase activity was measured using the luciferase assay system in the synergy H1 hybrid microplate reader. Relative levels of luciferase activity (mean ± SEM) are presented.

Statistical analyses
--------------------

The quantitative analysis of continuously distributed data is presented as scattered plots or box-and-whisker plots with quantitative elements, including, median with interquartile interval, minimum and maximum ranges. Statistical analysis performed using mean ± SEM using either Kaplan-Meier survival analysis, Log-rank (Mantel-Cox) test, one-way ANOVA or Student's *t*-test (unpaired, two-tailed) with GraphPad Prism (version 5.0d). A value of *P* ≤ 0.05 was considered significant. In all experiments with mice, '*n*' represents the number of mice used per group; and in experiments with tissues or cells, '*n*' represents the number of times experiment was performed. A minimum of *n =* 3 mice or number of times experiment performed was used in all the experiments, unless otherwise specified in an experiment.

Data availability
-----------------

The data that support the findings of this study are available from the corresponding author, upon reasonable request.

Results
=======

Generation of SMA mice with ZPR1 overexpression
-----------------------------------------------

To examine the *in vivo* effect of ZPR1 overexpression on modulation of SMA disease severity, we generated transgenic mice expressing the recombinant *Flag-Zpr1* gene under the control of the murine *Rosa26* promoter on an FVB genetic background to match with the SMAΔ7 model ([Supplementary Fig. 1A](#sup1){ref-type="supplementary-material"}). Transgene copy number analysis using Real-Time PCR copy number analysis (Applied Biosystems) revealed single copy integration into mouse genome. Heterozygous *Flag-Zpr1*^+/−^ mice were normal and fertile. Analysis of phenotype of homozygous *Flag-Zpr1^+^*^/*+*^ mice showed that female mice were normal and fertile but male mice developed inflammation of the genitals, and breeding potential, ability or interest to mate were compromised. However, male mice showed normal development and lifespan. We focused our analysis on heterozygous mice that provided an advantage to generate littermates with/without transgene for comparison. Next, we tested the functionality of recombinant ZPR1. Mutation of the *Zpr1*^−/−^ gene causes early (E3.5) embryonic lethality in mice ([@awz373-B16]). To test whether recombinant Flag-ZPR1 is a functional protein, we bred TFZP mice with *Zpr1*^+/−^ mice to rescue embryonic lethality of *Zpr1*^−/−^ mice. Embryonic lethality of *Zpr1*^−/−^ mice was rescued by recombinant Flag-ZPR1, rescued mice (*Zpr1*^−/−^; *Flag-Zpr1*^+/−^) were fertile and displayed normal phenotype and lifespan suggesting that the recombinant Flag-ZPR1 expresses during early embryonic development, retains biological activity and can complement for ZPR1 essential function ([Supplementary Fig. 1B and C](#sup1){ref-type="supplementary-material"}). We crossed *Flag-Zpr1*^+/−^ mice with SMAΔ7 mice and generated SMA carrier mice with *Flag-Zpr1* (*Smn*^+/−^; *SMN2^+^*^/*+*^; *SMNΔ7^+^*^/*+*^; *Flag-Zpr1*^+/−^). Homozygosity of transgenes, *SMN2* and *SMNΔ7*, in Z-SMA carrier mice was confirmed by PCR and breeding methods ([@awz373-B19]). SMA mice overexpressing ZPR1 (*Smn*^−/−^; *SMN2^+^*^/*+*^; *SMNΔ7^+^*^/*+*^; *Flag-Zpr1*^+/−^) are referred to as Z-SMA.

ZPR1 improves overall growth of SMA mice
----------------------------------------

SMA mice with ZPR1 overexpression (Z-SMA) were healthier, and were able to stand and walk compared to SMA mice (SMA) between the ages of 6 and 14 days. Initial observations suggested that ZPR1 overexpression might be beneficial in improving the overall health and gross motor function of SMA mice as shown in a photograph and a video clip of littermates with normal, SMA and Z-SMA genotypes ([Supplementary Fig. 1D, E](#sup1){ref-type="supplementary-material"} and [Supplementary Video 1](#sup1){ref-type="supplementary-material"}). Analysis of growth of littermates shows that ZPR1 improved average peak (mean ± SEM, *n =* 5) body weight (g) in Z-SMA males (5.19 ± 0.21, *P* = 0.0004) compared to SMA males (3.23 ± 0.22) and in Z-SMA females (4.17 ± 0.43, *P* = 0.0182) compared to SMA females (2.20 ± 0.46) ([Fig. 1](#awz373-F1){ref-type="fig"}A and B) . Comparison of combined (male + female) peak body weight of Z-SMA (4.684 ± 0.285) with SMA (2.719 ± 0.308) mice show statistically significant (*P* = 0.0003) improvement in growth of Z-SMA mice ([Fig. 1](#awz373-F1){ref-type="fig"}C). Gender-based analysis shows overall growth increase in Z-SMA females was ∼89% and in Z-SMA males was ∼61% compared to SMA females and males, respectively ([Fig. 1](#awz373-F1){ref-type="fig"}D--F). These data show better improvement in Z-SMA females with ∼28% higher body weight compared to Z-SMA males. Chronic SMN deficiency results in reduced embryonic growth and newborn human SMA babies have lower body weight compared to normal babies. Comparison of body weights at birth shows statistically significant (*P* = 0.0008) improvement in Z-SMA (1.642 ± 0.065, *n =* 20) compared to SMA (1.294 ± 0.069, *n =* 20) mice ([Fig. 1](#awz373-F1){ref-type="fig"}G). Comparison of body weight between normal (1.800 ± 0.064, *n =* 20), SMA and Z-SMA mice shows reduced weight loss in newborn pups of Z-SMA (0.16 g) compared to SMA (0.51 g), which shows 3.19-fold improvement in embryonic growth of Z-SMA mice (ANOVA, *P* \< 0.0001). ZPR1 overexpression also increased growth period from (7.00 ± 0.378, *n =* 7) (SMA) to (11.29 ± 0.285, *n =* 7) (Z-SMA) days, and shows ∼60% increase (*P* = 0.0001) in postnatal growth period ([Fig. 1](#awz373-F1){ref-type="fig"}H). These data suggest that *in vivo* ZPR1 overexpression improves embryonic and postnatal growth of Z-SMA mice, which may contribute to reduction of disease severity and increase the lifespan of SMA mice.

![**Genetic overexpression of the *Zpr1* gene improves overall growth and survival of SMA mice.** Overexpression of recombinant *Flag*-*Zpr1* gene under the control of mouse *Rosa26* promoter increases growth and the lifespan of mice with SMA (SMAΔ7). (**A**--**C**) ZPR1 overexpression improves growth of mice with SMA. Overall growth (body weight in grams) curves of normal (blue), Z-SMA (purple), and SMA (orange) mice littermates. Body weights recorded every day are presented as growth curves with mean ± SEM, *n =* minimum 3 mice/group for combined (male and female) group and for individual male and female groups. (**D**--**F**) Box and whisker plots and median with interquartile range (IQR) (minimum and maximum). (**D**) Average peak body weight (median, min, max) for males, SMA (3.27, 2.64, 3.74) and Z-SMA (5.15, 4.64, 5.91). (**E**) Average peak body weight for females, SMA (2.42, 0.98, 3.0) and Z-SMA (3.89, 3.43, 5.87). (**F**) Average peak body weight for combined males and females, SMA (2.92, 0.98, 3.74) and Z-SMA (4.78, 3.43, 5.91). These data show statistically significant increase in average peak body weight (g) of Z-SMA males (5.19 ± 0.21, *n =* 5) compared to SMA males (3.23 ± 0.22, *P* = 0.0004, unpaired *t*-test, two tailed), which represents ∼61% increase in body weight of Z-SMA males. Z-SMA females (4.17 ± 0.43, *n =* 5) compared to SMA females (2.20 ± 0.46, *P* = 0.0182) show ∼89% increase in peak body weight. Comparison of combined (male + female) peak body weight in Z-SMA (4.684 ± 0.285, *n =* 10) with SMA (2.719 ± 0.308, *P* = 0.0003) shows an average peak body weight increase of ∼72% in Z-SMA mice. (**G**) ZPR1 improves initial (embryonic) growth. Combined male and female growth (g) at birth for SMA (1.30, 0.77, 1.87) and Z-SMA (1.56, 1.15, 2.36). Statistical analysis shows significant improvement in initial growth of Z-SMA (1.642 ± 0.065, *n =* 20, *P* = 0.0008) compared to SMA (1.294 ± 0.069, *n =* 20) mice. (**H**) ZPR1 improves overall postnatal growth period of Z-SMA (11.0, 10.0, 12.0) compared to SMA (7.0, 5.0, 8.0) mice that increases from 7.00 ± 0.378 days (SMA, *n =* 7) to 11.29 ± 0.285 days (Z-SMA, *n =* 7), which shows ∼60% (*P* = 0.0001) increase in postnatal growth period. Growth analysis was blinded with colour coding. Gender and genotypes were confirmed by PCR-based method after euthanasia of pups. (**I**--**P**) ZPR1 overexpression improves survival of SMA mice. (**I**--**K**) Kaplan-Meier survival curves of normal (blue), Z-SMA (purple), and SMA (orange) mice littermates. Dotted lines show median survival. (**L**--**N**) Box-and-whisker plots with IQR show increase in (median, min, max) survival (days) of Z-SMA mice. (**L**) Z-SMA males (17.0, 16.0, 23.0) compared to SMA males (6.0, 1.0, 14.0). (**M**) Z-SMA females (18.0, 15.0, 22.0) compared to SMA females (6.0, 1.0, 14.0). (**N**) Z-SMA males and females (18.0, 15.0, 23.0) compared to SMA males and females (6.0, 1.0, 14.0). These data show ∼3-fold increase in median survival of Z-SMA mice compared to SMA mice. Statistical analysis of male and female survival show increase in average survival of Z-SMA (17.93 ± 0.34 days, *n =* 29) (Log-rank test, *P* \< 0.0001) compared to SMA (7.07 ± 0.78 days, *n =* 26) mice. Gender-based analysis show average survival of Z-SMA males (17.85 ± 0.56, *n =* 13) is higher than SMA males (7.38 ± 1.19, *n =* 13). Average survival of Z-SMA females (18.00 ± 0.43 days, *n =* 16) is also higher compared to SMA females (6.76 ± 1.05, *n =* 13). (**O**) Maximum survival of SMA males (M) and females (F) is 14 days and Z-SMA males is 23 days and females is 22 days. Increase in the lifespan among Z-SMA male + female (combined) is 2.53-fold (*P* \< 0.0001, *t*-test) compared to SMA mice. Increase in Z-SMA versus SMA males is 2.42-fold (*P* \< 0.0001) and Z-SMA versus SMA females is 2.66-fold (*P* \< 0.0001). (**P**) Scatter plot shows increase (15.5-fold) in initial survival of Z-SMA mice compared to SMA mice. All Z-SMA males and females survived at least 16 and 15 days, respectively, compared to SMA males and females that survived at least 1 day. Survival analysis was blinded with colour coding. Gender and genotypes were confirmed using a PCR-based method after euthanasia of pups.](awz373f1){#awz373-F1}

ZPR1 improves the lifespan of SMA mice
--------------------------------------

To determine whether ZPR1 overexpression improves the lifespan of SMA mice, we examined survival of SMA and Z-SMA littermates using Kaplan-Meier analysis. ZPR1 overexpression resulted in 2.53-fold increase in average (male and female) survival of Z-SMA mice (17.93 ± 0.34, *n =* 29) days compared to SMA (7.07 ± 0.78, *n =* 26) (Log-rank test, *P* \< 0.0001) ([Fig. 1](#awz373-F1){ref-type="fig"}I--K). Comparison of median survival of combined males and females shows 3.0-fold increase in the lifespan of Z-SMA mice ([Fig. 1](#awz373-F1){ref-type="fig"}K). Gender-based analysis shows average survival of Z-SMA males (17.85 ± 0.56, *n =* 13) and median survival (17.0 days) is higher than SMA males average (7.38 ± 1.19, *n =* 13) and median (6.0 days) survival ([Fig. 1](#awz373-F1){ref-type="fig"}I and L). Average survival of Z-SMA females (18.00 ± 0.43 days, *n =* 16) and median survival (18.0 days) is also higher than SMA females average (6.76 ± 1.05, *n =* 13) and median (6.0 days) survival ([Fig. 1](#awz373-F1){ref-type="fig"}J and M). Comparison of the average lifespan of Z-SMA males (2.42-fold) and females (2.66-fold) showed a ∼24% higher improvement in Z-SMA females than Z-SMA males ([Fig. 1](#awz373-F1){ref-type="fig"}I--K). These data are consistent with overall growth in Z-SMA females that is ∼28% higher compared to Z-SMA males ([Fig. 1](#awz373-F1){ref-type="fig"}A--C). Notably, 9 days increase in maximum survival of Z-SMA mice (∼64% increase in max lifespan) includes 6 days of growth (reduced severity) that shows about 67% of the total increase in the lifespan is with reduced severity of illness ([Fig. 1](#awz373-F1){ref-type="fig"}O). Analysis of initial survival shows a marked 15.5-fold increase in the initial survival of Z-SMA compared to SMA mice suggesting that every Z-SMA pup (*n =* 29), male or female, survived for at least 15 days after birth ([Fig. 1](#awz373-F1){ref-type="fig"}P). These data suggest that ZPR1 overexpression reduces postnatal disease severity, markedly decreases early mortality and increases the lifespan of Z-SMA mice.

ZPR1 improves gross motor function and muscle strength of SMA mice
------------------------------------------------------------------

Impaired gross motor functions and the loss of ability to walk are clinical features of SMA. To evaluate beneficial effects of ZPR1 overexpression, we examined gross motor functions, ability to right, stand on paws and walk. The ability to stand on paws and walk (time in seconds) was improved in Z-SMA mice (30.61 ± 1.82, *P* \< 0.0001) compared to SMA mice (2.55 ± 0.15) ([Fig. 2](#awz373-F2){ref-type="fig"}A). Video clip of 12-day-old three littermates \[normal, SMA (smallest), Z-SMA (black mark on the tail)\] shows SMA pup has severe defects in ability to right and stand on paws and unable to walk. In contrast, the Z-SMA pup was able to walk and right itself within a few seconds and continues to walk ([Supplementary Video 1](#sup1){ref-type="supplementary-material"}). The representative video clip shows that the Z-SMA mouse is able to right itself at the age of 12 days. These data show ZPR1 overexpression results in marked improvement in the ability of Z-SMA mice to walk.

![**ZPR1 overexpression improves gross motor function and muscle strength of SMA mice.** (**A**) ZPR1 improves ability to stand on paws and walk. Ability to stand on paws and walk was determined by measuring the time to fall off in an effort to walk, and was recorded in 12-day-old SMA and Z-SMA littermates. Comparison of latency to fall (s) from paws presented as a box-and-whisker plot with IQR (median, min, max) for SMA (2.49, 2.0, 3.0) and Z-SMA (31.50, 24.66, 36.00) showing all Z-SMA pups were able to stand and walk for a median time of ∼30 s, suggesting improvement in gross motor function. Statistical analysis of (mean ± SEM, *n =* 6 mice/group) (s) between SMA (2.55 ± 0.15) and Z-SMA (30.61 ± 1.82), *P* \< 0.0001 (unpaired *t*-test, two-tailed) for 12-day-old mice shows marked improvement in the ability of Z-SMA mice to stand on paws and walk (see [Supplementary Video 1](#sup1){ref-type="supplementary-material"}). (**B**) Ability of mice to right was recorded for 5--18-day-old normal (blue), SMA (orange), and Z-SMA (purple) littermates with all three genotypes present in the same litter. Time-to-right (TTR) with a time limit of 30 s for test and average of three recordings per pup are plotted. Data were collected using *n =* 10 (normal), 8 (SMA), and 10 (Z-SMA) mice groups are presented as a scatter plot. (**C**) Improvement in the motor function is demonstrated by increase in the ability of mice to right faster in Z-SMA mice compared to SMA mice is shown as box-and-whisker plots (median, min, max) starting from PND10 \[SMA (26.17, 5.67, 30.0) and Z-SMA (6.83, 1.0, 30.0)\], PND11 \[SMA (20.50, 4.33, 30.0) and Z-SMA (5.33, 2.67, 19.0)\], PND12 \[SMA (30.0, 30.0, 30.0) and Z-SMA (3.0, 1.33, 30.0)\], PND13 \[SMA (30.0, 30.0, 30.0) and Z-SMA (3.33, 1.0, 30.0)\], PND14 \[SMA (30.0, 30.0, 30.0) and Z-SMA (1.33, 1.33, 30.0)\]. Statistical analysis of (mean ± SEM) shows significant improvement in Z-SMA mice from PND10 \[SMA (20.58 ± 3.97, *n =* 8) and Z-SMA (9.70 ± 2.76, *n =* 10), *t*-test, *P* = 0.034), PND11 \[SMA (18.67 ± 5.14, *n =* 6) and Z-SMA (6.36 ± 1.60, *n =* 10), *P* = 0.014), PND12 \[SMA (30.00 ± 1.00, *n =* 4) and Z-SMA (8.43 ± 3.61, *n =* 10), *P* = 0.003\], PND13 \[SMA (30.00 ± 1.00, *n =* 4) and Z-SMA (9.60 ± 3.56, *n =* 10), *P* = 0.004\] to PND14 \[SMA (30.00 ± 1.00, *n =* 4) and Z-SMA (5.36 ± 3.1, *n =* 10), *P* = 0.0005\]. (**D**) The hind-limb suspension test (HLST) shows ZPR1 improves muscle strength in mice with SMA. Littermates aged 5--8 days were hung by both hind legs on the edge of a 50 ml plastic conical tube and time (s) was recorded until fall from the edge of the tube. Latency to fall (mean ± SEM, 6 mice/group) shown as a scatter plot and (**E**) as scatter plots with median with IQR (median, min, max) for each time point (day), PND5 \[SMA (16.0, 4.0, 26.67) and Z-SMA (20.84, 16.0, 23.67)\], PND6 \[SMA (10.0, 6.0, 29.67) and Z-SMA (25.67, 16.33, 30.0)\], PND7 \[SMA (6.5, 5.0, 14.0) and Z-SMA (16.34, 13.0, 28.0)\], PND8 \[SMA (4.67, 2.0, 11.70) and Z-SMA (19.67, 10.33, 25.33)\]. Statistical analysis (*t*-test, unpaired) shows marked increase (*P* = 0.0301) in hanging time for Z-SMA compared to SMA with increasing age PND5 \[Z-SMA (20.00 ± 1.23) and SMA (16.61 ± 3.73), *P* = 0.408\], PND6 \[Z-SMA (24.16 ± 2.11) and SMA (14.50 ± 3.97), *P* = 0.057\], PND7 \[Z-SMA (17.61 ± 2.15) and SMA (7.445 ± 1.3762), *P* = 0.002\], PND8 \[Z-SMA (18.60 ± 2.42) and SMA (5.26 ± 2.22), *P* = 0.005\] shows gradual increase in muscle strength of Z-SMA mice compared to SMA mice.](awz373f2){#awz373-F2}

To gain insight into improvement in gross motor function during postnatal development, we examined time-to-right (TTR) for 5--18-day-old pups with a test time of 30 s ([@awz373-B19]). Analysis of TTR shows statistically significant improvement in the motor function of Z-SMA compared to SMA mice starting from postnatal day (PND)10 \[SMA (20.58 ± 3.97, *n =* 8) and Z-SMA (9.70 ± 2.76, *n =* 10), *P* = 0.0342\] to PND14 \[SMA (30.00 ± 1.0, *n =* 4) and Z-SMA (5.36 ± 3.1, *n =* 10), *P* = 0.0005\] ([Fig. 2](#awz373-F2){ref-type="fig"}B and C). All SMA pups in this assay were dead by Day 14. However, Z-SMA pups showed continued improvement in their ability to right until PND17 (2.44 ± 0.55, *n =* 3) ([Fig. 2](#awz373-F2){ref-type="fig"}B). The ability to right for Z-SMA pups began declining from PND18 and mice were unable to right by PND20. Increase in inability to right with reduction in TTR of Z-SMA compared to SMA mice with increasing age suggest gradual improvement in the gross motor function and reduction in disease severity of Z-SMA mice during postnatal development.

Improvement in motor function of Z-SMA mice suggest possibility of increase in muscle strength, to test whether ZPR1 also increases muscle strength, we used a hind-limb suspension test to evaluate improvement in the proximal hind-limb muscle strength ([@awz373-B12]; [@awz373-B2]; [@awz373-B19]). Five to eight-day-old mice were hung by both hind legs on the edge of a 50 ml plastic conical tube fitted with soft cotton pad at the bottom, and time was recorded until fall from the edge of tube. Comparison of latency to fall (seconds) between Z-SMA (20.00 ± 1.23, *n =* 6) and SMA (16.61 ± 3.73, *n =* 6) at PND5 did not show statistically significant difference (*P* = 0.4087) ([Fig. 2](#awz373-F2){ref-type="fig"}D and E). However, a marked increase in hanging time of Z-SMA compared to SMA mice was found at PND6 \[SMA (14.50 ± 3.97) and Z-SMA (24.16 ± 2.11, *P* = 0.057)\], PND7 (SMA (7.445 ± 1.3762) and Z-SMA (17.61 ± 2.15, *P* = 0.0026) and PND8 (SMA (5.26 ± 2.22) and Z-SMA (18.60 ± 2.42, *P* = 0.0052)\]. An increase in hind-limb suspension test time suggests improvement in hind-limb muscle strength of Z-SMA mice compared to SMA mice. Together, these data suggest that ZPR1 overexpression improves muscle strength and gross motor function of Z-SMA mice.

ZPR1 reduces neuron degeneration, improves neuromuscular junction innervation and muscle fibre size in SMA mice
---------------------------------------------------------------------------------------------------------------

Downregulation of ZPR1 has been shown to contribute to neurodegeneration and severity of SMA disease in mice ([@awz373-B9]; [@awz373-B2]). To test whether *in vivo* ZPR1 overexpression will help reduce neurodegeneration and contribute to the rescue of SMA phenotype, we examined motor neurons in the spinal cords of normal, SMA and Z-SMA mice. Immunohistochemical staining of the spinal cord sections with antibodies against ChAT and SMN showed reduced loss of motor neurons in Z-SMA compared to SMA mice ([Fig. 3](#awz373-F3){ref-type="fig"}A). Comparison of number of motor neurons in the lumbar (L1--L5) region of spinal cords (mean ± SEM%, three mice per group) of 7-day-old normal (101.20 ± 4.03%, *n =* 3), SMA (47.03 ± 2.85%) and Z-SMA (71.55 ± 2.24%) mice shows that ZPR1 overexpression reduced the loss of motor neurons by (24.52 ± 3.63%, *P* = 0.0025)% in Z-SMA compared to SMA mice and provided neuroprotection by increasing survival of neurons up to (71.55 ± 2.24%, *P* \< 0.0001) in Z-SMA compared to normal and SMA mice ([Fig. 3](#awz373-F3){ref-type="fig"}B).

![**ZPR1 overexpression reduces neuron degeneration, improves NMJ innervation and muscle fibre size in SMA mice.** (**A**) ZPR1 reduces loss of spinal cord motor neurons in mice with SMA. Immunohistochemical staining of the lumbar region spinal cord sections from 7-day-old normal, SMA, and Z-SMA littermates with anti-ChAT and SMN antibodies. Scale bar = 50 µm. (**B**) ZPR1 increases survival of SMN-deficient spinal cord motor neurons from SMA mice. Box-and-whisker plot with median and IQR (median, min, max) shows increase in the relative number of motor neurons (20 sections/mice, 3 mice/group) in the lumbar region of the spinal cords from Z-SMA (70.50, 60.0, 86.0) compared to SMA (47.0, 36.0, 61.0). Statistical analysis using mean ± SEM and comparison between SMA (47.03 ± 2.85%, *n =* 3) and Z-SMA (71.55 ± 2.24%) compared with normal (non-SMA) mice (littermates) as a reference point (101.20 ± 4.03%) shows statistically significant increase (24.52 ± 3.63%) in the number of motor neurons in Z-SMA mice, SMA versus Z-SMA (*P* = 0.0025, *t*-test, unpaired) and normal versus SMA versus Z-SMA (*P* \< 0.0001, ANOVA). (**C**) ZPR1 reduces muscle degeneration in mice with SMA. Immunohistochemical staining of hind limb muscles, tibialis anterior longitudinal sections with β-actin (*top*) and transverse sections with dystrophin (*bottom*) from normal, SMA, and Z-SMA littermates. Scale bar = 50 µm (*top*) and 25 µm (*bottom*). (**D**) Immunohistochemical staining of hind limb muscles, gastrocnemius longitudinal sections with β-actin (*top*) and transverse sections with dystrophin (*bottom*) from normal, SMA, and Z-SMA littermates. Scale bar = 50 µm (*top*) and 25 µm (*bottom*). (**E**) ZPR1 improves muscle fibre diameter of SMA mice. The diameter of individual muscle fibres (μm) was measuring using transverse sections of gastrocnemius muscle from normal (blue), SMA (orange), and Z-SMA (purple) littermates stained with dystrophin. Diameter was measured at three different points, including longest and shortest along the irregular circular shape of each fibre and averaged. One hundred fibres per mouse (three mice per group) were measured to determine myofibres diameter. Scatter plots with median, min, max range for normal (17.61, 14.53, 20.44), SMA (11.53, 6.16, 15.30) and Z-SMA (13.87, 8.55, 17.97) show distribution of myofibre diameters. Statistical analysis shows increase in mean diameter (µm) for Z-SMA (13.88 ± 0.91) compared to SMA (11.06 ± 0.31), *P* = 0.043. (**F**) Immunohistochemical staining of gastrocnemius skeletal muscle with antibody to neurofilament M protein (NF, green) and BTX coupled with Alexa 594 (red) from normal, SMA, and Z-SMA littermates. Scale bars = 25 µm. (**G**) Immunohistochemical staining of gastrocnemius skeletal muscle with antibody to synaptophysin (SYN, red) and neurofilament (NF, green) from normal, SMA, and Z-SMA littermates. Scale bars = 25 µm. Note that littermates for all three genotypes were present in the same litter.](awz373f3){#awz373-F3}

Improvement in gross motor functions, increased hind limb strength ([Fig. 2](#awz373-F2){ref-type="fig"}) and reduced loss of motor neurons in Z-SMA mice suggest the possibility of improvement in muscle growth and function. Immunohistochemical analysis of hind limb muscles, tibialis anterior and gastrocnemius skeletal muscles, performed by staining longitudinal and transverse sections with antibodies against dystrophin and β-actin (markers for muscle morphology) shows marked improvement with reduced muscle atrophy in Z-SMA compared to SMA mice ([Fig. 3](#awz373-F3){ref-type="fig"}C and D). Analysis of muscle fibre diameter using scatter plots shows reduced variation in myofibre size and increased mean diameter (μm) in Z-SMA mice (13.88 ± 0.91) compared to SMA mice (11.06 ± 0.31) with *P* = 0.043 ([Fig. 3](#awz373-F3){ref-type="fig"}E). Comparison of muscle fibre thickness (μm) between normal (17.52 ± 0.90), SMA (11.06 ± 0.31) and Z-SMA (13.88 ± 0.91) show increase (∼21%, *P* = 0.043) in muscle fibre diameter of Z-SMA compared to SMA mice ([Fig. 3](#awz373-F3){ref-type="fig"}E).

Neuron degeneration, including axonal retraction results in poor innervations of neuromuscular junctions (NMJs) leading to defects in maturation of NMJs in SMA patients and SMA mice ([@awz373-B53]; [@awz373-B19]). To test whether neuroprotection provided by ZPR1 overexpression will improve NMJs, we examined hind-leg gastrocnemius skeletal muscle stained with BTX and antibody against NF-M protein to visualize acetylcholine receptors (AChRs) and nerves, respectively. Comparison of NMJs innervation, indicated by co-localization of AChRs and NF staining, shows improved innervations of NMJs in Z-SMA compared to SMA mice that have NMJs with partial or full denervation ([Fig. 3](#awz373-F3){ref-type="fig"}F). Neuron degeneration coupled with NMJs denervation causes defects in synapse formation and contributes to synaptopathy in SMA. Defects in synaptic maturation and reduced levels of synapse formation have been shown to be present in SMA animal models ([@awz373-B53]; [@awz373-B19]). To determine whether ZPR1 also improves synaptic maturation in Z-SMA mice, we examined gastrocnemius muscle stained with antibodies against NF-M and synaptophysin. SMA mice show NMJs with reduced innervation, retracting nerve fibres and marked reduction in synaptophysin staining compared to Z-SMA mice ([Fig. 3](#awz373-F3){ref-type="fig"}G). ZPR1 overexpression results in increased synaptophysin staining of NMJs in Z-SMA and show marked improvement in synapse formation in Z-SMA compared to SMA mice ([Fig. 3](#awz373-F3){ref-type="fig"}G). Together, these data show ZPR1 overexpression results in improvement of motor neuron survival, NMJs innervation, gross motor function, overall growth and the lifespan of Z-SMA mice, which suggest amelioration of severe SMA phenotype to moderate SMA phenotype.

Mechanism of improvement in SMA phenotype by ZPR1
-------------------------------------------------

The immunohistochemical staining of spinal cord sections with SMN antibodies reproducibly showed increased staining for SMN in Z-SMA compared to SMA mice, which suggests an increase in SMN levels in Z-SMA mice ([Fig. 3](#awz373-F3){ref-type="fig"}A, bottom). To determine whether improvement in phenotype of Z-SMA mice is SMN-dependent, we examined effect of ZPR1 overexpression on SMN levels in neuronal, brain and spinal cord and non-neuronal, heart, lung, liver and muscle tissues that are affected in SMA ([@awz373-B46]) using automated capillary western blot analysis ([@awz373-B20]; [@awz373-B27]). Quantitative (mean ± SEM, *n =* 3 mice/group) and statistical analysis of relative protein levels normalized to tubulin with reference to normal mice (100%) show marked increase in levels of SMN protein in Z-SMA mice spinal cord (74.42 ± 7.44%, *P* = 0.0031) and brain (62.82 ± 5.43%, *P* = 0.0015) compared to SMA spinal cord (23.86 ± 2.62%) and brain (20.33 ± 0.45%) tissues, respectively ([Fig. 4](#awz373-F4){ref-type="fig"}A, B and G). Analysis of ZPR1 shows downregulation of endogenous ZPR1 levels (∼40--45%) in the brain and spinal cord, and in non-neuronal tissues, heart, lung, liver and muscle from SMA mice ([Fig. 4](#awz373-F4){ref-type="fig"}A--F, H, and [Supplementary Figs 2 and 3](#sup1){ref-type="supplementary-material"}) suggesting systemic downregulation of ZPR1 (∼40--50%) in SMA mice, which is consistent with downregulation of ZPR1 reported in SMA patients ([@awz373-B23]; [@awz373-B2]). Analysis of total ZPR1 and recombinant Flag-ZPR1 levels shows a large increase (∼3-fold) in total ZPR1 levels in the spinal cord and brain tissues of Z-SMA compared to SMA mice ([Fig. 4](#awz373-F4){ref-type="fig"}A, B and H). Analysis of SMN levels shows similar increase in the spinal cord \[3.12-fold (*P* = 0.0031)\] and brain \[3.09-fold (*P* = 0.0015)\] tissues of Z-SMA compared to SMA mice ([Fig. 4](#awz373-F4){ref-type="fig"}I). These data suggest that increase in SMN levels by ZPR1 overexpression *in vivo* may have a direct correlation between ZPR1 and SMN levels in the CNS of SMA mice.

![**ZPR1 overexpression increases SMN levels in neuronal and non-neuronal tissues and leads to SMN-dependent amelioration of SMA phenotype. Proteins levels of SMN, ZPR1, Flag-ZPR1 and tubulin were examined by immunoblot analysis of mouse tissues**. (**A**) spinal cord, (**B**) brain, (**C**) heart, (**D**) lung, (**E**) liver and (**F**) muscle from 7-day-old normal, SMA and Z-SMA mice using automated capillary Wes™ System (ProteinSimple) and quantification was performed using Compass software. Representative capillary-blot images of proteins are shown (full-length blots are provided in [Supplementary Figs 2 and 3](#sup1){ref-type="supplementary-material"}). Quantitative data are shown as a scatter plot with median, min and max; (median, min, max) range shows relative increase in SMN levels (%) in different tissues by ZPR1 overexpression in the: (**G**) spinal cord \[SMA (25.96, 18.65, 26.98) and Z-SMA (77.32, 60.32, 85.63)\], brain \[SMA (19.96, 19.79, 21.24) and Z-SMA (57.93, 56.87, 73.67)\], heart \[SMA (15.76, 14.62, 22.36) and Z-SMA (49.61, 49.60, 60.32)\], lung \[SMA (15.61, 12.58, 26.19) and Z-SMA (55.69, 43.72, 65.36)\], liver \[SMA (14.82, 6.13, 30.98) and Z-SMA (20.20, 17.18, 28.65)\] and muscle \[SMA (14.78, 10.32, 20.36) and Z-SMA (20.36, 19.32, 25.63)\] and statistical analysis (unpaired *t*-test) of protein levels (mean ± SEM, *n =* 3 mice/group) shows that ZPR1 overexpression resulted in statistically significant increase of SMN levels in the spinal cord of Z-SMA (74.42 ± 7.44, *P* = 0.0031) compared to SMA (23.86 ± 2.62), brain of Z-SMA (62.82 ± 5.43, *P* = 0.0015) compared to SMA (20.33 ± 0.45), heart of Z-SMA (53.18 ± 3.57, *P* = 0.0012) compared to SMA (17.58 ± 2.41), lung of Z-SMA (54.92 ± 6.25, *P* = 0.0080) compared to SMA (18.13 ± 4.12) but not in the liver of Z-SMA (22.01 ± 3.43, *P* = 0.5907) compared to SMA (17.31 ± 7.27) and muscle of Z-SMA (21.77 ± 1.95, *P* = 0.1317) compared to SMA (15.15 ± 2.90) relative to respective normal mice tissues protein levels (100%) normalized to tubulin. (**H**) Quantitative analysis of increase in relative levels (%) of total ZPR1 expression in the: spinal cord \[SMA (50.36, 45.63, 66.36) and Z-SMA (153.47, 146.73, 187.32)\], brain \[SMA (59.34, 44.50, 70.12) and Z-SMA (171.80, 165.32, 178.36)\], heart \[SMA (61.36, 55.48, 62.36) and Z-SMA (163.06, 147.51, 164.91)\], lung \[SMA (61.89, 58.50, 63.35) and Z-SMA (170.76, 124.33, 175.32)\], liver \[SMA (59.99, 40.32, 69.97) and Z-SMA (80.36, 54.32, 90.32)\] and muscle \[SMA (50.32, 37.39, 65.95) and Z-SMA (75.66, 38.25, 92.04)\]. Statistical analysis of increase in levels of total ZPR1 protein using antibody against ZPR1 shows increase in ZPR1 levels in the spinal cord of Z-SMA (162.50 ± 12.56, *P* = 0.0015) compared to SMA (54.12 ± 6.27), brain of Z-SMA (171.80 ± 3.76, *P* = 0.0002) compared to SMA (57.99 ± 7.42), heart of Z-SMA (158.50 ± 5.51, *P* = 0.0001) compared to SMA (59.73 ± 2.14), lung of Z-SMA (156.80 ± 16.29, *P* = 0.0043) compared to SMA (61.25 ± 1.43), liver of Z-SMA (75.00 ± 10.73, *P* = 0.2574) compared to SMA (56.76 ± 8.71) and muscle of Z-SMA (68.65 ± 15.92, *P* = 0.3861) compared to SMA (51.22 ± 8.25) relative to respective normal mouse tissue protein levels (100%) normalized to tubulin. (**I**) Quantitative data are presented as a scatter plot with median, min and max range shows relative increase in SMN levels in different tissues as fold change in Z-SMA mice compared to SMA mice; spinal cord (3.11 ± 0.31, *P* = 0.0031), brain (3.08 ± 0.26, *P* = 0.0015), heart (3.02 ± 0.20, *P* = 0.0012), lung (3.029 ± 0.34, *P* = 0.0080), liver (1.27 ± 0.19, *P* = 0.5911) and muscle (1.43 ± 0.13, *P* = 0.1333) relative to respective SMA mice tissues protein levels (100% or 1.0-fold) normalized to tubulin. (**J**) Quantitative data are shown as a scatter plot with median, min and max range shows relative expression (%) of recombinant Flag-ZPR1 in Z-SMA mice; spinal cord (100.027 ± 3.71), brain (84.36 ± 3.05), heart (64.86 ± 2.50), lung (61.17 ± 2.62), liver (24.98 ± 3.47) and muscle (20.78 ± 0.80) relative to Z-SMA spinal cord Flag-ZPR1 levels (100%) normalized to tubulin.](awz373f4){#awz373-F4}

To gain insight into ZPR1-dependent systemic increase in SMN levels, we examined levels of SMN in non-neuronal tissues, heart, lung, liver and skeletal muscle that are also affected by chronic low levels of SMN in SMA ([@awz373-B46]). Quantitation shows an increase in SMN levels (∼3-fold) in the heart (*P* = 0.0012) and lung (*P* = 0.0080) tissues of Z-SMA compared to SMA mice ([Fig. 4](#awz373-F1){ref-type="fig"}C, D, G and I). Analysis of total ZPR1 levels shows increase in the heart (2.65-fold, *P* \< 0.0001) and lung (2.56-fold, *P* = 0.0043) in Z-SMA compared to SMA mice. In contrast, liver and muscle show a small and statistically non-significant increase in SMN \[1.27-fold (*P* = 0.5911) and \[1.43-fold (*P* = 0.1333), respectively\] in Z-SMA compared to SMA mice ([Fig. 4](#awz373-F4){ref-type="fig"}E--G). ZPR1 levels also shows a small and non-significant increase in liver (1.32-fold, *P* = 0.2577) and muscle (1.34-fold, *P* = 0.3876) of Z-SMA mice compared to SMA mice ([Fig. 4](#awz373-F4){ref-type="fig"}H). Analysis of Flag-ZPR1 levels in all examined tissues shows the lowest levels in the liver (24.98 ± 3.47%) and muscle (20.78 ± 0.80%) tissues relative to the spinal cord (100%) ([Fig. 4](#awz373-F4){ref-type="fig"}J). These data suggest that low levels of Flag-ZPR1 in liver and muscle tissues may be because of reduced expression of the *Rosa26* promoter in these tissues. Analysis of data from different tissues shows that a 2--3-fold increase in ZPR1 is required for a corresponding 2--3-fold increase in SMN, suggesting a direct correlation between ZPR1 and SMN levels. Together, these data suggest that ZPR1-mediated improvement in SMA phenotype is SMN-dependent.

ZPR1 clears R-loops and rescues DNA damage in SMN-deficient spinal cord neurons and SMA mice
--------------------------------------------------------------------------------------------

Chronic low levels of SMN causes molecular defects that include downregulation of SETX and DNA-activated protein kinase catalytic subunit (DNA-PKcs), which lead to DNA damage accumulation and neurodegeneration in SMA ([@awz373-B27]). SETX is an RNA/DNA helicase required for resolution of RNA-DNA hybrids (R-loops) ([@awz373-B49]). SETX deficiency causes accumulation of R-loops, which results in double-stranded DNA breaks leading to genomic instability. DNA-PKcs is essential for non-homologous end joining (NHEJ)-mediated double strand break repair ([@awz373-B8]). Neurons predominantly use NHEJ for DNA repair ([@awz373-B43]). Therefore, combined deficiency of SETX and DNA-PKcs results in gradual accumulation of DNA damage because of inefficient NHEJ-mediated DNA repair leading to genomic instability and predominant degeneration of motor neurons in SMA ([@awz373-B27]). Notably, ectopic increase in SMN levels restores SETX and DNA-PKcs levels and rescues DNA damage in SMA motor neurons and SMA patient cells ([@awz373-B27]). To test whether ZPR1-dependent increase in SMN will restore levels of SETX and DNA-PKcs and reduce DNA damage in SMA, we examined spinal cords and quantitation shows that ZPR1 overexpression increases SETX levels in Z-SMA (93.66 ± 13.39%, *P* = 0.0199) compared to (40.30 ± 4.80%) in SMA ([Fig. 5](#awz373-F5){ref-type="fig"}A, B and [Supplementary Fig. 4](#sup1){ref-type="supplementary-material"}). ZPR1 also increases levels of DNA-PKcs in Z-SMA (88.11 ± 13.12%, *P* = 0.0133) compared to (29.36 ± 4.48%) in SMA ([Fig. 5](#awz373-F5){ref-type="fig"}A and B), which results in increased levels of phospho (p)-DNA-PKcs in Z-SMA (85.13 ± 11.62%, *P* = 0.0175) compared to (36.41 ± 4.58%) in SMA ([Fig. 5](#awz373-F5){ref-type="fig"}A and B) suggesting an increase in DNA-PKcs activity to enhance NHEJ-mediated DNA repair. Examination of activation of DNA damage response response marker, γH2AX (phospho-H2AX), shows marked reduction (2.5-fold, *P* = 0.0009) in γH2AX levels in Z-SMA compared to SMA mice suggesting decrease in DNA damage in Z-SMA mice ([Fig. 5](#awz373-F5){ref-type="fig"}A and B). Together, these data show that ZPR1 overexpression increases SETX and p-DNA-PKcs levels, which downregulates DNA damage response and rescue DNA damage in Z-SMA mice.

![**ZPR1 rescues molecular defects and DNA damage associated with SMA pathogenesis in SMA motor neurons and SMA mice.** Protein extracts were prepared from the spinal cords isolated from 7-day-old normal, SMAΔ7 (SMA) and Z-SMA mice, and examined using an automated capillary-based western blot system. Representative capillary-blot images of proteins are shown (full-length blots are provided in [Supplementary Fig. 4](#sup1){ref-type="supplementary-material"}). (**A**) Immunoblot analysis of spinal cord protein extracts. (**B**) Quantitative immunoblot data are presented as a scatter plot with median, min and max (median, min, max) range shows relative change (%) in levels of SMN and DNA damage markers caused by *in vivo* ZPR1 overexpression in the spinal cords of mice, SMN \[SMA (25.64, 20.65, 27.98) and Z-SMA (75.69, 62.65, 75.69)\], SETX \[SMA (38.95, 32.74, 49.21) and Z-SMA (82.32, 78.32, 120.33)\], p-DNA-PKcs \[SMA (33.65, 30.21, 45.36) and Z-SMA (83.65, 65.79, 105.96)\], total DNA-PKcs \[SMA (31.70, 20.69, 35.68) and Z-SMA (84.65, 67.32, 112.36)\] and γH2AX \[SMA (302.69, 298.63, 330.25) and Z-SMA (130.65, 85.63, 150.32)\]. Statistical analysis (mean ± SEM, *n =* 3 mice/group) using *t*-test (unpaired, two-tailed) of proteins shows increase in ZPR1 (167.40 ± 9.55%, *P* = 0.0005) in Z-SMA compared to ZPR1 (47.99 ± 6.78%) levels in SMA mice results in increase of SMN (73.33 ± 5.61%, *P* = 0.0013) in Z-SMA compared to SMN (24.76 ± 2.16%) levels in SMA mice, SETX (93.66 ± 13.39%, *P* = 0.0199) in Z-SMA compared to SETX (40.30 ± 4.80%) levels in SMA mice, phospho-DNA-PKcs (p-DNAPKcs) (85.13 ± 11.62%, *P* = 0.0175) in Z-SMA compared to p-DNA-PKcs (36.41 ± 4.58%) levels in SMA mice and total DNA-PKcs (88.11 ± 13.12%, *P* = 0.0133) in Z-SMA compared to DNA-PKcs (29.36 ± 4.48%) levels in SMA mice. Analysis of DNA damage response marker shows decrease in γH2AX (122.20 ± 19.15%, *P* = 0.0009) in Z-SMA compared to γH2AX (310.5 ± 9.93%) levels in SMA mice suggesting the rescue of DNA damage *in vivo* by ZPR1 overexpression. (**C** and **D**) Primary spinal cord neurons were cultured from 7-day-old normal, SMA and Z-SMA mice. (**C**) Neurons were stained with ZPR1 and (**D**) R-loops (S9.6) antibodies and high magnification images of nuclei are presented. Dotted ellipses represent nuclei. Scale bar = 5.0 μm. (**E**) Quantitative analysis of relative levels of accumulation of nuclear R-loops in motor neurons from normal, SMA and Z-SMA mice is presented as a scatter plot with IQR (median, min, max), normal (118.0, 65.25, 118.7), SMA (734.90, 709.40, 978.9) and Z-SMA (141.8, 118.20, 306.90). Statistical analyses (mean ± SEM, *n =* 3 experiments, 50 neurons/experiment) using *t-*test (unpaired, two-tailed) of accumulation of R-loops in SMA (807.7 ± 85.90%, *P* = 0.0013) and normal neurons (106 ± 17.69%) shows large (∼8-fold) increase in accumulation of R-loops in SMA compared to normal mice. Comparison of R-loop accumulation between SMA (807.7 ± 85.90) and Z-SMA (189.0 ± 59.36) using *t*-test (*P* = 0.0041) and comparison between normal, SMA and Z-SMA using ANOVA (*P* = 0.0003) shows statistically significant decrease in *in vivo* R-loop accumulation by ZPR1 overexpression in Z-SMA mice. (**F** and **G**) HeLa cells were transfected with mock (Control), antisense ZPR1 oligonucleotide (As-ZPR1) and scrambled oligonucleotides (Scramble) (100 nM). (**F**) Knockdown of ZPR1 results in accumulation of R-loops (green) in the nucleus and formation 53BP1 foci (red) suggesting DNA double-strand breaks (DSBs). (**G**) ZPR1 (green) knockdown results in loss ZPR1 nuclear foci and causes accumulation of γH2AX foci (red) suggesting activation of DNA damage response in response to DNA damage caused by ZPR1 deficiency. Scale bar = 5 μm. (**H**--**L**) Cultured primary spinal cord neurons from SMA mice were infected with adenovirus (100 MOI) expressing green fluorescent protein (GFP) (Ad-GFP) and ZPR1-GFP fusion protein (Ad-ZPR1-GFP) and stained with antibodies against neuron-specific β-tubulin-III (red), SMN, SETX, p-DNA-PKcs, R-loops and γH2AX, and immunofluorescence was examined by confocal microscopy. GFP and ZPR1-GFP (green) were detected by GFP fluorescence. Axonal defects include retraction, bending, folding of axons (arrowheads) that indicate degeneration of SMN-deficient neurons. (**H**) Staining of neurons with SMN (cyan) and β-tubulin (red), (**I**) SETX (cyan) and β-tubulin (red), (**J**) p-DNA-PKcs (cyan) and β-tubulin (red), (**K**) γH2AX (cyan) and β-tubulin (red) and (**L**) R-loops (cyan) and β-tubulin (red). SMA neurons with ZPR1 ectopic expression (Ad-ZPR1-GFP panels) show reduction in neuron degenerative features. Nuclei were stained with DAPI (blue). Scale bar = 25 μm. Enlarged images of merged panels (**H**--**L**) are included in [Supplementary Fig. 5](#sup1){ref-type="supplementary-material"} to show features of axonal degeneration such as loosening, bending retraction and ballooning in SMA neurons. (**M**) Immunoblot analysis of *in vitro* cultured motor neurons from SMA mice expressing GFP (Ad-GFP) and ZPR1-GFP (Ad-ZPR1-GFP) for changes in levels of SMN and DNA damage markers, SETX, p-DNA-PKcs, total DNA-PKcs and γH2AX. (**N**) Quantitative immunoblot data are presented as a scatter plot with median, min and max range shows relative change (%) in levels of SMN and DNA damage markers caused by *in vitro* ZPR1 overexpression in cultured motor neurons from SMA mice, SMN \[SMA+GFP (17.06, 15.02, 29.0) and SMA+ZPR1-GFP (87.32, 79.06, 108.63)\], SETX \[SMA+GFP (45.62, 39.52, 65.32) and SMA+ZPR1-GFP (120.69, 105.36, 145.63)\], p-DNA-PKcs \[SMA+GFP (34.56, 30.65, 40.31) and SMA+ZPR1-GFP (102.36, 89.65, 109.65)\], total DNA-PKcs \[SMA+GFP (35.62, 30.65, 45.98) and SMA+ZPR1-GFP (115.47, 91.20, 138.97)\] and γH2AX \[SMA+GFP (108.90, 104.04, 118.99) and SMA+ZPR1-GFP (19.45, 14.13, 28.96)\]. Statistical analysis using unpaired *t*-test of quantitative data (mean ± SEM, *n =* 3 mice/group) from spinal cord neuron immunoblots shows increase in ZPR1 levels (5.14 ± 0.44, *P* = 0.0010)-fold results in marked increase in levels of SMN (4.50 ± 0.43, *P* = 0.0019)-fold, SETX (2.47 ± 0.23, *P* = 0.0075)-fold, p-DNA-PKcs (2.85 ± 0.16, *P* = 0.0006)-fold and total DNA-PKcs (3.07 ± 0.36, *P* = 0.0059)-fold leading to decrease in γH2AX levels (5.04 ± 0.03, *P* = 0.0002)-fold. These data suggest the rescue of DNA damage in SMA spinal cord neurons (full-length blots are provided in [Supplementary Fig. 6](#sup1){ref-type="supplementary-material"}). (**O**) Enlarged images of nuclei of neurons stained with S9.6 antibody (R-loops, pseudocoloured orange) from SMA+Ad-GFP (SMA) and SMA+Ad-ZPR1-GFP (SMA+ZPR1) groups of SMA neurons. (**P**) Quantitative and statistical analysis of R-loop accumulation in cultured SMA motor neurons, SMA+GFP (103.5, 92.80, 103.7) and SMA+ZPR1-GFP (21.36, 19.65, 27.89) shows reduced accumulation (22.97 ± 2.51%, *P* \< 0.0001) in neurons overexpressing ZPR1 (SMA+ZPR1-GFP) compared SMA+ GFP neurons.](awz373f5){#awz373-F5}

Genomic instability is caused by R-loop accumulation during transcription that leads to selective degeneration of motor neurons in SMA ([@awz373-B27]). To gain insight into the effect of ZPR1 overexpression on R-loop accumulation, we examined cultured primary neurons isolated from the spinal cords of 7-day-old, normal, SMA and Z-SMA mice and stained with antibodies against ZPR1 and R-loops (S9.6). We have previously shown that cultured primary spinal cord neurons from postnatal mice stain positive for known motor neuron markers, such as homeobox Hlxb9 (Hb9) and ChAT, suggesting that cultured spinal cord neurons may have characteristics similar to motor neurons ([@awz373-B2]; [@awz373-B19]; [@awz373-B27]). Immunofluorescence analysis of neurons stained with neuron-specific β-tubulin shows that neurons from Z-SMA mice were healthy and were rescued of axonal degeneration defects compared to neurons from SMA mice. SMA neurons show reduced accumulation of ZPR1 in the nucleus compared to normal neurons ([Fig. 5](#awz373-F5){ref-type="fig"}C) and is consistent with data from patient cells ([@awz373-B18]). Neurons from Z-SMA show increased accumulation of ZPR1 in the nucleus compared to SMA suggesting that deficiency of ZPR1 in the nucleus of SMA (SMN-deficient) neurons is rescued by ZPR1 overexpression ([Fig. 5](#awz373-F5){ref-type="fig"}C). Comparison of R-loops shows ∼8-fold higher accumulation in SMA compared to normal (*P* = 0.0013). Interestingly, ZPR1 overexpression results in ∼4.3-fold (*P* = 0.0041) reduction in R-loop accumulation in Z-SMA ([Fig. 5](#awz373-F5){ref-type="fig"}D and E) suggesting that ZPR1 can complement and decrease R-loops *in vivo* in SMN-deficient neurons. These data raise an interesting question: does ZPR1-deficiency causes R-loop accumulation and contributes to genomic instability associated with SMA pathogenesis ([@awz373-B27])? To address this, we examined the effect of ZPR1 knockdown on HeLa cells, which showed that ZPR1-deficiency causes accumulation of R-loops and DNA damage as suggested by activation of DNA damage response markers, γH2AX and 53BP1 ([Fig. 5](#awz373-F5){ref-type="fig"}F and G). These data suggest that ZPR1-deficiency may contribute to R-loop accumulation and DNA damage associated with SMA. ZPR1 overexpression and reduction in R-loop accumulation in Z-SMA neurons suggest that ZPR1 may contribute to resolution of R-loops generated during transcription and supports putative function of ZPR1 in transcription ([@awz373-B15]).

To test whether ZPR1 can also prevent DNA damage *in vitro* in SMA neurons, we performed a rescue experiment by complementation with adenovirus expressing ZPR1-GFP using *in vitro* cultured primary spinal cords neurons from SMA mice ([@awz373-B19]; [@awz373-B27]). We have recently shown that an increase in SETX levels alone can rescue molecular defects associated with DNA damage in SMA neurons and SMA patients cells. Therefore, we focused our analysis of ZPR1 overexpression on increase in SETX levels, reduction in R-loop accumulation and the rescue of DNA damage ([@awz373-B27]). SMA neurons were infected with adenovirus containing GFP (Ad-GFP) and recombinant human ZPR1-GFP (Ad-ZPR1-GFP), stained with antibodies against tubulin, SMN, SETX, p-DNA-PKcs, R-loops (S9.6), and γH2AX. Control SMA neurons expressing GFP show axonal degeneration, bending, retraction and folding that is consistent with previous findings ([@awz373-B19]; [@awz373-B27]), suggesting that GFP did not alter phenotype of SMN-deficient spinal cord neurons from SMA mice ([Fig. 5](#awz373-F5){ref-type="fig"}H--L, Ad-GFP panels). Neurons expressing ZPR1-GFP (Ad-ZPR1-GFP) show increase in SMN staining and the rescue of neurodegenerative features such as axonal bending, swelling, ballooning, retraction and folding compared to GFP expressing SMA neurons ([Fig. 5](#awz373-F5){ref-type="fig"}H--L, Ad-ZPR1-GFP panels). Protein analysis show that Ad-ZPR1-GFP expression increases total ZPR1 levels (5.14-fold, *P* = 0.0010) compared control neurons with Ad-GFP ([Fig. 5](#awz373-F5){ref-type="fig"}M and N). Notably, ZPR1-GFP overexpression increases SMN levels by 4.5-fold (*P* = 0.0019) ([Fig. 5](#awz373-F5){ref-type="fig"}H, M and N), increases levels of SETX (2.47-fold, *P* = 0.0075) ([Fig. 5](#awz373-F5){ref-type="fig"}I, M and N), p-DNA-PKcs (2.85 ± 0.16, *P* = 0.0006)-fold and total DNA-PKcs (3.07 ± 0.36, *P* = 0.0059)-fold ([Fig. 5](#awz373-F5){ref-type="fig"}J, M and N), and decreases γH2AX levels by 5.04-fold (*P* = 0.0002) ([Fig. 5](#awz373-F5){ref-type="fig"}K, M and N) suggesting reduction in double strand break accumulation and downregulation of DNA damage response. Further, examination of neurons stained with an antibody (S9.6) against R-loops shows marked reduction (4.35-fold, *P* \< 0.0001) in R-loops suggesting that increase in SETX levels by ZPR1 results in reduced accumulation of R-loops in SMA neurons ([Fig. 5](#awz373-F5){ref-type="fig"}L, O and P). These data show that ZPR1-dependent restoration of SMN levels in SMA neurons increase SETX levels, which reduce R-loop accumulation, and increase DNA-PKcs levels, which repairs DNA double-strand breaks, and together rescue DNA damage in SMA neurons. Thus, these results suggest an important role for ZPR1 in maintaining optimal levels of SMN and its downstream targets SETX and DNA-PKcs critical for resolving R-loops and DNA repair, respectively, to avert genomic instability and prevent degeneration of motor neurons in SMA.

ZPR1 rescues molecular defects and DNA damage in SMA patient cells
------------------------------------------------------------------

To test whether the molecular defects associated with DNA damage can be rescued by ZPR1 in SMA type I patient-derived primary fibroblasts, we performed a rescue experiment with ectopic expression of recombinant ZPR1-GFP protein. Comparison of control GFP transfected and non-transfected cells show that GFP expression did not alter the phenotype of SMA patient cells and is consistent with previous findings ([Fig. 6](#awz373-F6){ref-type="fig"}A--H) ([@awz373-B27]). Ectopic expression of ZPR1-GFP induces accumulation of SMN in the nucleus of transfected cells compared to non-transfected in GM03813 and GM09677 cells as shown in [Fig. 6](#awz373-F6){ref-type="fig"}A and E. Quantitative analysis shows an increase in ZPR1 levels (∼4.5-fold) elevated SMN levels in GM03813 (4.5-fold, *P* = 0.0009) ([Fig. 6](#awz373-F1){ref-type="fig"}A, I and J) and GM09677 (5.1-fold, *P* = 0.0095) cells ([Fig. 6](#awz373-F6){ref-type="fig"}E, K, L and [Supplementary Figs 7 and 8](#sup1){ref-type="supplementary-material"}). Notably, ZPR1 also increased SETX levels 2.0-fold (*P* = 0.0049) in GM03813 ([Fig. 6](#awz373-F1){ref-type="fig"}B, I and J) and 1.9-fold (*P* = 0.0061) in GM09677 cells ([Fig. 6](#awz373-F6){ref-type="fig"}F, K and L). Cells stained with antibody against R-loops show reduced accumulation of R-loops in the nucleus of cells expressing ZPR1-GFP compared to non-transfected or GFP transfected cells ([Fig. 6](#awz373-F6){ref-type="fig"}C and G). Quantitation of nuclear R-loop shows decrease in GM03813 (4.55-fold, *P* = 0.00015) and GM09677 (4.0-fold, *P* = 0.00008) cells expressing ZPR1-GFP compared control cells suggesting that increase in SETX levels by ZPR1 reduces R-loop accumulation in SMA patient cells ([Fig. 6](#awz373-F6){ref-type="fig"}B, C, F and G).

![**Complementation with ZPR1 rescues senataxin levels and DNA damage in SMA patient cells.** SMA patient primary fibroblast cell lines, GM03813 (**A**--**D**) and GM09677 (**E**--**H**) were transfected with phrGFP (GFP) or phrZPR1-GFP (ZPR1-GFP), fixed and stained with antibodies against SMN, SETX, R-loops and γH2AX. Ectopic ZPR1 expression elevates levels of SMN and SETX and reduces R-loop accumulation and rescues DNA damage in SMA patient cells. (**A** and **E**) SMN (red) and ZPR1-GFP (green), (**B** and **F**) SETX (red) and ZPR1-GFP, (**C** and **G**) R-loops (red) and ZPR1-GFP, (**D** and **H**) γH2AX (red) and ZPR1-GFP. Nuclei were stained with DAPI (blue). Scale bar = 5.0 μm. Arrows show transfected cells and asterisks indicate non-transfected cells. (**I**--**L**) Effect of ZPR1 overexpression on SMN, SETX, and γH2AX levels in patient cells GM03813 (I-J) and GM09677 (K-L) examined by IB (full-length blots are provided in [Supplementary Figs 7 and 8](#sup1){ref-type="supplementary-material"}). (**I**) Immunoblot analysis of patient cells (GM03813) expressing GFP and ZPR1-GFP. (**J**) Quantitative immunoblot data are presented as a scatter plot with IQR (median, min, max) shows relative change (%) in levels of SMN, SETX and γH2AX caused by *in vitro* ZPR1 overexpression in SMA patient cells (GM03813), SMN \[GFP (21.28, 16.83, 27.44) and ZPR1-GFP (98.65, 85.69, 114.67)\], SETX \[GFP (55.69, 47.96, 68.52) and ZPR1-GFP (120.36, 102.36, 132.65)\] and γH2AX \[GFP (125.69, 106.59, 146.96) and ZPR1-GFP (22.65, 10.96, 30.32)\]. Statistical analysis of quantitative data from GM03813 (GFP) and GM03813 (ZPR1-GFP) cells show ZPR1 overexpression (4.37 ± 0.25, *P* = 0.0003)-fold increases levels of SMN (4.56 ± 0.38, *P* = 0.0009)-fold and SETX (2.06 ± 0.15, *P* = 0.0049)-fold and result in marked reduction of γH2AX levels (6.0 ± 0.04, *P* = 0.0012)-fold in (GM03813+ZPR1-GFP) compared to control GM03813+GFP cells suggesting rescue of DNA damage in patient cells by ZPR1 complementation. (**K**) Immunoblot analysis of patient cells (GM09677) expressing GFP and ZPR1-GFP. (**L**) Quantitative immunoblot data are presented as a scatter plot with IQR (median, min, max) shows relative change (%) in levels of SMN, SETX and γH2AX caused by *in vitro* ZPR1 overexpression in SMA patient cells (GM09677), SMN \[GFP (20.05, 17.65, 24.08) and ZPR1-GFP (102.32, 76.92, 139.52)\], SETX \[GFP (59.68, 38.69, 70.26) and ZPR1-GFP (106.98, 99.87, 111.36)\] and γH2AX \[GFP (121.8, 103.04, 151.52) and ZPR1-GFP (22.98, 14.65, 25.36)\]. Statistical analysis of quantitative data from GM09677+GFP and GM09677+ZPR1-GFP cells shows (4.51 ± 0.42, *P* = 0.0015)-fold increase in ZPR1, which results in marked reduction of γH2AX levels (6.08 ± 0.026, *P* = 0.0018)-fold compared to GM09677+GFP suggesting the rescue of DNA damage that is supported by increase in levels of SMN (5.15 ± 0.88%, *P* = 0.0095)-fold and SETX (1.88 ± 0.059, *P* = 0.0061)-fold in ZPR1-GFP complemented patient cells compared to patient cells with GFP.](awz373f6){#awz373-F6}

Furthermore, immunofluorescence analysis of ZPR1 overexpressing cells stained for γH2AX shows reduced γH2AX staining and foci in transfected compared to non-transfected GM03813 and GM09677 cells ([Fig. 6](#awz373-F6){ref-type="fig"}D and H). Quantitation shows marked reduction in the levels of γH2AX in GM03813 (6.0-fold, *P* = 0.0012) ([Fig. 6](#awz373-F6){ref-type="fig"}I and J) and GM09677 (6.08-fold, *P* = 0.0018) cells complemented with ZPR1 suggesting that ZPR1 is able to rescue DNA damage in SMA patient cells ([Fig. 6](#awz373-F6){ref-type="fig"}K and L). Together, these data on ZPR1-mediated increase in SMN and SETX levels leads to reduction in R-loop accumulation and the rescue of DNA damage in patient cells suggest that ZPR1 has potential to rescue the molecular defects associated with SMA pathogenesis, in SMA neurons and patient cells and represents an SMN-dependent protective modifier of SMA.

ZPR1 transcriptionally upregulates *SMN2* expression in SMA patient cells and SMA mice
--------------------------------------------------------------------------------------

ZPR1 may have functions in mRNA biogenesis, including transcription and may be a putative transcription factor ([@awz373-B15]; [@awz373-B28]). To test the function of ZPR1 as a transcriptional regulator and unravel the molecular mechanism of ZPR1-mediated increase in SMN protein levels, we examined *in vitro* and *in vivo* effects of ZPR1 overexpression on *SMN2* transcripts, full-length *SMN* and *SMNΔ7*, in SMA patient cells and Z-SMA mice using qPCR. Comparative analysis of *in vivo* transcription data from the spinal cords show increase (2.93 ± 0.33-fold, *P* = 0.0060) in *SMNΔ7* and (2.65 ± 0.30-fold, *n =* 3, *P* = 0.0058) in full-length *SMN* transcripts in Z-SMA compared to SMA mice ([Fig. 7](#awz373-F7){ref-type="fig"}A). Analysis of SMA patient fibroblast with ectopic expression of recombinant Flag-ZPR1 shows increase in *SMNΔ7* (4.00 ± 0.25-fold, *P* = 0.0003) and full-length *SMN* transcripts (3.42 ± 0.62-fold, *P* = 0.0249) in GM03813+ZPR1 (SMA+ZPR1) compared to control (transfected with empty vector) GM03813 cells (SMA) ([Fig. 7](#awz373-F7){ref-type="fig"}B). Examination of second SMA patient fibroblast cell line (GM09677) also shows increase in *SMNΔ7* (3.58 ± 0.22-fold, *P* = 0.0008) and in full-length *SMN* transcripts (3.04 ± 0.21-fold, *P* = 0.0054) in GM09677+ZPR1 (SMA+ZPR1) compared to control GM09677 cells (SMA) ([Fig. 7](#awz373-F7){ref-type="fig"}C). We also examined the effect of ZPR1 on change in relative abundance of *SMN* and *SMNΔ7* transcripts in SMA and Z-SMA mice that shows proportionate ∼3-fold increase in both transcripts in Z-SMA mice ([Fig. 7](#awz373-F7){ref-type="fig"}D). Similar increase (\>3-fold) in both transcripts was found in SMA patient cell lines complemented with recombinant ZPR1 ([Fig. 7](#awz373-F7){ref-type="fig"}E and F). The higher levels of *SMNΔ7* compared to *SMN* transcript in mice and patient cells is because of one copy each of *SMN2* and *SMNΔ7* cDNA in mice and three copies of *SMN2* gene in both cell lines, respectively, and is consistent with the published data that *SMN2* produces majority of *SMNΔ7* transcript ([Fig. 7](#awz373-F7){ref-type="fig"}D--F) ([@awz373-B34]; [@awz373-B51]). These data show that ZPR1 overexpression increases overall transcription of *SMN2* gene *in vitro* (patient cells) and *in vivo* (SMA mice) under pathophysiological conditions of SMA suggesting that ZPR1 may be a positive transcriptional regulator of the *SMN2* gene.

![**ZPR1 overexpression upregulates *SMN2* gene transcription in SMA patient cells and SMA mice.** (**A**) ZPR1 overexpression *in vivo* upregulates total *SMN2* transcription under SMA conditions. Total RNA was isolated from the spinal cords of 7-day-old SMA and Z-SMA littermates and examined by qPCR using specific primers for amplification of *SMNΔ7* and full-length *SMN* transcripts generated from *SMN2*. The relative mRNA levels were calculated using fold-enrichment (2^−ΔΔCT^) method and presented as a scatter plot with median, min and max range. Quantitative data for *SMNΔ7* \[SMA (1.08, 0.74, 1.16) and Z-SMA (2.96, 2.32, 3.50)\] and *SMN* \[SMA (0.98, 0.91, 1.12) and Z-SMA (2.63, 2.14, 3.18)\]. ZPR1 overexpression increases full-length *SMN* (2.65 ± 0.30-fold, *n =* 3, *P* = 0.0058) and *SMNΔ7* (2.93 ± 0.33-fold, *P* = 0.0060) transcript levels in Z-SMA mice compared to SMA mice. (**B**) SMA patient cell lines GM03813 was transfected with pcDNA3 or pcDNA3/Flag-ZPR1. The scatter plot shows quantitative data for *SMNΔ7* \[SMA (0.96, 0.92, 1.12) and SMA+ZPR1 (3.87, 3.64, 4.5)\] and *SMN* \[SMA (1.28, 0.65, 1.34) and SMA+ZPR1 (3.12, 2.51, 4.62)\]. Statistical analysis shows ectopic ZPR1 overexpression increases full-length *SMN* (3.42 ± 0.62-fold, *P* = 0.0249) and *SMNΔ7* (4.00 ± 0.25-fold, *P* = 0.0003) transcript levels in GM03813+ZPR1 (SMA+ZPR1) compared to control GM03813 (SMA) patient cells. (**C**) SMA patient cell line GM09677 was transfected with pcDNA3 or pcDNA3/Flag-ZPR1. Quantitative data for *SMNΔ7* \[SMA (0.94, 0.93, 1.42) and SMA+ZPR1 (3.57, 3.21, 3.98)\] and *SMN* \[SMA (1.03, 0.60, 1.59) and SMA+ZPR1 (2.86, 2.79, 3.48)\]. Statistical analysis shows that ZPR1 increases full-length *SMN* (3.04 ± 0.21-fold, *P* = 0.0054) and *SMNΔ7* (3.58 ± 0.22-fold, *P* = 0.0008) transcript levels in GM09677+ZPR1 (SMA+ZPR1) compared to control GM09677 (SMA) patient cells. (**D**--**F**) Analysis of relative abundance of *SMN* and *SMNΔ7* transcripts in (**D**) SMA and Z-SMA mice, and (**E**) SMA patient cell line (GM03813) and (**F**) SMA patient cell line (GM09677) without and with ZPR1 overexpression using qPCR. (**G--N**) ZPR1 interacts with RNA polymerase and *in vivo* associates with genomic *SMN* locus. Modulation of ZPR1 levels influences *SMN* expression. (**G**) Immunoprecipitation with anti-ZPR1 antibody shows pulldown of RNAPII from wild-type mouse brain protein extract suggesting *in vivo* interaction of ZPR1 with RNAPII. (**H**) GST-ZPR1 pulldown of RNAPII from HeLa cell lysate shows *in vitro* direct interaction of ZPR1 with RNAPII. (**I**--**J**) ZPR1 interacts with genomic *SMN* locus *in vivo*. Chromatin immunoprecipitation (ChIP) was performed using antibodies against ZPR1, H3K4me3 (positive control) and FLAG (M2) antibody (negative control) and chromatin prepared from human HeLa cells. Presence of *SMN* genomic locus in ChIP was detected by real-time qPCR using primers in the human *SMN* promoter region and *SMN* exon 1 region. ChIP assay shows ZPR1 associates with *SMN* locus and result in 4.34 ± 0.38-fold (*n =* 3, *P* = 0.0004) (promoter) and 3.66 ± 0.43-fold (*P* = 0.0012) (*SMN* exon 1) regions amplifications compared to control (IgG). (**K**--**L**) Modulation of ZPR1 levels influences expression of *SMN1-Luc* and *SMN2-Luc* reporter genes. (**K**) Effect of ZPR1 knockdown on ectopic *SMN1* and *SMN2* genes expression in cultured HeLa cells. Cells were transfected with either *SMN1-Luc* or *SMN2-Luc* or empty control reporter vector (Con-Luc). Transfected cells were retransfected after 24 h with scrambled or *ZPR1* antisense oligonucleotides (As-ZPR1) to knockdown the levels of ZPR1. Cells were harvested after 24 h post-second transfection for determination of luciferase activity or (**M**) immunoblot analysis for ZPR1 expression. To examine the effect of ZPR1 overexpression, HeLa cells were transfected with combination of two plasmids: (i) Con-Luc + pcDNA3-*FlagZPR1*, (ii) SMN1-Luc or SMN2-Luc + pcDNA3 (empty); and (iii) SMN1-Luc or SMN2-Luc + pcDNA3-*FlagZPR1*. After 30 h post-transfection, cells were harvested for determining luciferase activity or (**N**) immunoblot analysis for ZPR1 expression. Quantification of luciferase activity shows ZPR1 knockdown causes decreases and ZPR1 overexpression increases levels of *SMN1* and *SMN2* promoters driven luciferase expression. Scatter plot with median, min and max range shows modulation of luciferase activity for SMN1-Luc (106.70, 80.48, 112.9), SMN1-Luc+As-ZPR1 (26.14, 15.59, 27.23) and SMN1-Luc+Flag-ZPR1 (227.6, 180.9, 260.0). SMN2-Luc (98.41, 97.67, 103.90), SMN2-Luc+As-ZPR1 (13.72, 9.28, 20.19) and SMN2-Luc+Flag-ZPR1 (160.10, 141.6, 178.9). Statistical analysis (mean ± SEM; *n =* 3) shows ZPR1 knockdown reduced levels of luciferase activity of SMN1-Luc to 22.99 ± 3.71% (*P* = 0.001) and SMN2-Luc to 14.40 ± 3.16% (*P* \< 0.0001) in cells treated with antisense oligonucleotides compared to control cells with scrambled oligo. ZPR1 overexpression results in increase of luciferase activity for SMN1-Luc to 222.8 ± 22.95% (*P* = 0.0062) and SMN2-Luc to 160.2 ± 10.76% (*P* = 0.014) compared to cells without ZPR1 overexpression (full-length blots are provided in [Supplementary Fig. 9](#sup1){ref-type="supplementary-material"}).](awz373f7){#awz373-F7}

ZPR1 interacts with RNA polymerase, associates *in vivo* with *SMN* genomic locus and regulates *SMN* transcription
-------------------------------------------------------------------------------------------------------------------

The above data on enhancement of *SMN2* transcription by ZPR1 suggest that ZPR1 may be a componenet of RNA transcription complexes; therefore, we examined the interaction of ZPR1 with RNA polymerase II (RNAPII). Immunoprecipitation with anti-ZPR1 antibody and pulldown with GST-ZPR1 followed by western blot analysis shows that ZPR1 interacts *in vivo* with RNAPII ([Fig. 7](#awz373-F7){ref-type="fig"}G) and ZPR1 may interact directly with RNAPII ([Fig. 7](#awz373-F7){ref-type="fig"}H) suggesting that ZPR1 is a part of the basal transcription complex containing RNAPII. These data support the idea that downregulation of ZPR1 in SMA patients may contribute to reduced transcription of *SMN2* and the low levels of SMN, which is further supported by our current data that ZPR1 overexpression enhances *SMN2* transcription and levels of SMN protein in SMA mice and patient cells.

To strengthen the idea that ZPR1 is a transcriptional regulator of *SMN* genes, we tested whether ZPR1 interacts *in vivo* with *SMN* genomic locus, we performed ChIP with antibodies against H3K4me3 (positive control) and ZPR1, and control antibody (negative control) followed by qPCR to measure binding of ZPR1 with *SMN* genes using promoter and exon 1 primers with sequences identical in *SMN1* and *SMN2* genes. The ChIP-PCR assay using primers, which amplify promoter region (−622 to −430) of *SMN1* and *SMN2* genes, show that ZPR1 antibody pulldown results in 4.34 ± 0.38-fold (*P* = 0.0004) amplification compared to IgG control ([Fig. 7](#awz373-F7){ref-type="fig"}I). Similarly, PCR with exon 1 region primers shows 3.66 ± 0.43-fold (*P* = 0.0012) amplification of *SMN* genes compared to IgG control ([Fig. 7](#awz373-F7){ref-type="fig"}J). Together, these data show that ZPR1 interacts *in vivo* with RNAPII and associates with genomic *SMN* locus on chromosome 5q13 suggesting that ZPR1 is a part of the core transcription complex and may be involved in transcriptional regulation of *SMN* expression.

Furthermore, to test whether modulation of ZPR1 levels influence transcription of both *SMN1* and *SMN2* gene and ZPR1 may be a transcriptional regulator of *SMN* genes, we examined the effect of change in ZPR1 levels using *in vitro* biochemical experiments. To examine the effect of ZPR1 on transcription, we used plasmids containing the luciferase (Luc) gene under the control of human *SMN1* and *SMN2* promoter regions (750 bp DNA sequences upstream of start codon) ([@awz373-B38]) and transfected HeLa cells to measure the luciferase enzyme activity. ZPR1 levels were: (i) downregulated by knockdown using antisense oligonucleotide ([@awz373-B15]); and (ii) upregulated by ectopic expression of recombinant human *Flag-ZPR1* cDNA ([@awz373-B2]; [@awz373-B20]). Knockdown of ZPR1 levels (As-ZPR1) causes marked reduction in luciferase activity in cells expressing *SMN1-Luc* (22.99 ± 3.71%, *P* = 0.001) ([Fig. 7](#awz373-F7){ref-type="fig"}K) and *SMN2-Luc* (14.40 ± 3.16%, *P* \< 0.0001) ([Fig. 7](#awz373-F7){ref-type="fig"}L) compared to cells treated with scrambled oligonucleotide. Notably, overexpression of ZPR1 (Flag-ZPR1) results in increase of luciferase activity in cells expressing *SMN1-Luc* (222.80 ± 22.95%, *P* = 0.006) ([Fig. 7](#awz373-F7){ref-type="fig"}K) and *SMN2-Luc* (160.20 ± 10.76%, *P* = 0.014) ([Fig. 7](#awz373-F7){ref-type="fig"}L) compared to control cells (pcDNA3) without ZPR1 overexpression ([Fig. 7](#awz373-F7){ref-type="fig"}M, N and [Supplementary Fig. 9](#sup1){ref-type="supplementary-material"}). The increase in *SMN2* promoter activity is consistent with *in vivo* increase in the levels of transcription and SMN protein levels, which are upregulated by *Zpr1* gene overexpression in Z-SMA mice and SMA patient cells. These findings suggest that modulation of ZPR1 levels directly correlates and influences levels of *SMN* genes transcription and ZPR1 is a transcriptional regulator of the *SMN1* and *SMN2* genes.

Discussion
==========

Chronic low levels of SMN result in motor neuron degeneration causing skeletal muscle atrophy leading to respiratory failure and death in SMA. The severity of SMA disease ranges from SMA type I (severe) to type IV (mild) and is inversely correlated with SMN levels, which are dependent on copy number of the *SMN2* gene in SMA patients that have homozygous *SMN1* deletion or mutation ([@awz373-B32]; [@awz373-B55]). Each copy of the *SMN2* gene produces ∼10% SMN protein and variation in *SMN2* copy number causes proportionate changes in SMN levels and result in a broad clinical spectrum of SMA patients with varying severity of disease ([@awz373-B34]; [@awz373-B55]). These findings have established *SMN2* as a naturally occurring modifier of disease severity with tremendous therapeutic potential for SMN-dependent rescue of SMA. Two methods can be used for producing higher amounts of SMN from *SMN2*: (i) correction of pre-mRNA splicing; and (ii) upregulation of transcription of the *SMN2* gene. Excellent progress has been made in the past decade to develop a therapeutic method using antisense oligonucleotides to correct splicing of the *SMN2* gene and approved by FDA as the first drug (nusinersen; SPINRAZA®) to treat SMA ([@awz373-B47]). However, there are challenges that need to be addressed, including side effects and complications in patients, which are discussed in recent papers ([@awz373-B52]). In contrast, only modest progress has been made towards understanding the transcriptional regulation of the *SMN2* gene. *Cis* regulatory elements have been identified in the promotor region of the *SMN2* gene but the transcription factors that may regulate expression of the *SMN2* gene have not been reported ([@awz373-B41]). In this study, we demonstrate that ZPR1 is a positive transcriptional regulator of both *SMN1* and *SMN2* genes. ZPR1 overexpression in SMA patient cells (*in vitro*) and SMA mice (*in vivo*) enhances *SMN2* transcription, which increases SMN protein levels and results in an SMN-dependent amelioration of severe SMA phenotype to moderate SMA phenotype ([Fig. 8](#awz373-F8){ref-type="fig"}).

![**Graphical summary: the molecular mechanism of ZPR1-dependent rescue of spinal muscular atrophy.** ZPR1 interacts with RNAPII and associates *in vivo* with SMA 5q13 genomic locus. ZPR1 levels are downregulated in SMA. Low levels of ZPR1 result in reduced transcription of *SMN2* gene leading to chronic low levels of SMN in SMA. Low levels of SMN cause deficiency of senataxin (SETX), which results in accumulation of RNA-DNA hybrids (R-loops). Accumulation of R-loops causes DNA double-strand breaks (DSBs) and activation of DNA damage response (DDR). In dividing cells, double strand breaks are repaired by homologous recombination (HR) and NHEJ, but neurons predominantly use NHEJ that requires DNA-PKcs activity. Chronic low levels of SMN cause deficiency of DNA-PKcs that causes defects in NHEJ-mediated double strand break repair leading to genome instability and predominant degeneration of motor neurons in SMA. ZPR1 overexpression in SMA increases transcription of *SMN2* gene resulting in higher levels of SMN. Increase in SMN elevates SETX and DNA-PKcs levels that result in reduction of R-loops and the rescue of DNA damage leading to neuroprotection and amelioration of severe to moderate SMA disease phenotype.](awz373f8){#awz373-F8}

Mechanism of ZPR1-mediated transcriptional upregulation of the *SMN2* gene in SMA
---------------------------------------------------------------------------------

Transcriptional regulation of *SMN1* and *SMN2* genes is poorly understood. Initial studies have identified a promoter region within 3.4 kb and a core promoter within 750 bp upstream of the start codon. Several common consensus DNA *cis* elements, including HNF-3beta, HiNF, IRF-E/ISRE, Elk-1, CREB, Sp1, MAZ, AhR, HNF-3 and N-Oct3 that are known to regulate gene expression are present in the core promoter regions of *SMN1* and *SMN2* genes ([@awz373-B11]; [@awz373-B21]). Preliminary studies suggest that transcriptional regulation modulates *SMN* genes expression during development and cellular differentiation. However, specific *trans*-acting/transcription factors that may regulate expression of *SMN* genes remain to be identified.

The human *ZPR1* gene is located on Chr11q23.2 and is evolutionary conserved in eukaryotes and encodes a protein with two C4-type Zn^2+^ fingers with novel helix-loop-helix motifs that may mediate protein-protein and protein-nucleic acid interactions ([@awz373-B36]). Genetic studies in yeast and mice have shown that the *ZPR1* is an essential gene ([@awz373-B13]; [@awz373-B17], [@awz373-B16]). However, the essential biological function of ZPR1 is unknown. Biochemical studies have provided insight that ZPR1 interacts with eEF1A and the SMN protein ([@awz373-B17], [@awz373-B18]). ZPR1 mediates receptor tyrosine kinases (RTKs) signalling by binding to the cytoplasmic domain of epidermal growth factor receptor (EGFR) and platelet-derived growth factor receptor (PDGFR), which is highly conserved among family of RTKs ([@awz373-B14]). In quiescent mammalian cells, ZPR1 binds to inactive EGFR and PDGFR, upon mitogen or serum treatment, ZPR1 translocates from the cytoplasm to the nucleus and triggers mitosis suggesting that ZPR1 may play an important role in nuclear processes involving expression of genes required for the cell growth and proliferation ([@awz373-B14], [@awz373-B13]). The precise function of ZPR1 in the nucleus is unclear. However, ZPR1 deficiency causes defects in splicing and transcription ([@awz373-B18], [@awz373-B16]; [@awz373-B15]). Recent studies showed that ZPR1 may be a putative transcription factor that regulate light regulated genes in plants and developmentally regulated *Hox* genes in mammals ([@awz373-B28]; [@awz373-B20]). ZPR1 *in vivo* interacts with SMN and is required for accumulation of SMN in sub-nuclear bodies, including gems and Cajal bodies. Interaction of ZPR1 with SMN is indirect ([@awz373-B18], [@awz373-B16]). Our data demonstrate that ZPR1 interacts *in vivo* and *in vitro* with RNAPII and is a part of transcription complexes. A recent study demonstrated that SMN interacts with RNAPII and is a part of transcription complexes and the disruption of RNAPII-SMN complexes by mutation in RNAPII causes defects in transcription termination ([@awz373-B57]). Direct interaction of ZPR1 with RNAPII suggests that ZPR1 and SMN interaction may be mediated *in vivo* by RNAPII. ZPR1 and SMN may play distinct roles in transcription. SMN has been shown to play a critical role in pre-mRNA splicing ([@awz373-B42]) and our data show that the ZPR1 may play a role in regulation of pre-mRNA transcription by contributing to resolution of co-transcriptional R-loops. Accumulation of R-loops in cells is a major cause of DNA damage and genomic instability leading to human diseases, including neurodegenerative disorders ([@awz373-B50]; [@awz373-B27]).

Binding of ZPR1 with RNAPII and its *in vivo* association with genomic SMA (5q13) locus suggest that ZPR1 may be a part of core transcription complexes. However, whether ZPR1 is a specific *trans*-acting factor or transcriptional enhancer that has a specific DNA binding site or has broad specificity and interacts with nucleic acids as a part of core transcription complexes, and regulates transcription is unclear and requires further studies. Our current data demonstrate that ZPR1 may play a role in resolution of R-loops that are formed during transcription and regulates transcription but the molecular mechanism of ZPR1-dependent R-loop resolution and transcriptional regulation is unclear. However, knockdown of ZPR1 in HeLa cells results in accumulation of R-loops and DNA damage, which is consistent with data on accumulation of R-loops in SMA patient cells that have low levels of ZPR1, suggesting that ZPR1 deficiency causes R-loop accumulation and contributes to genomic instability that leads to neurodegeneration in SMA ([@awz373-B2]; [@awz373-B27]). Because ZPR1 interacts with RNAPII and is a part of core transcription complexes, it is possible that ZPR1 may be required for resolution of co-transcriptional R-loops.

Modulation of ZPR1 levels *in vitro* by knockdown or overexpression in cultured cells causes downregulation or upregulation of recombinant *SMN1-Luc* and *SMN2-Luc* expression levels, respectively, suggesting a direct correlation between ZPR1 and SMN levels. This is supported by *in vivo* data of ZPR1 overexpression in Z-SMA mice on upregulation of *SMN2* gene transcription and increase in SMN levels in Z-SMA mice that show ∼3-fold increase in ZPR1 expression results in ∼3-fold increase in SMN levels, which is further supported by *in vitro* data on upregulation of endogenous *SMN2* transcription and SMN levels by ZPR1 in SMA patient fibroblast that show ∼4--5-fold increase in ZPR1 expression results in ∼4--5-fold increase in SMN transcript and protein levels. The higher levels of transcripts and SMN protein in patient cells complemented with Flag-ZPR1 compared to Z-SMA mice could be because of three copies of *SMN2* present in GM03813 and GM09677 cell lines ([@awz373-B51]). Together, our current data demonstrate that ZPR1 is a positive transcriptional regulator of *SMN2* gene and supports the idea that it could be exploited for its therapeutic potential to treat SMA using pharmacological method to upregulate *ZPR1* expression to elevate SMN levels.

SMN-dependent systemic improvement of SMA phenotype by ZPR1
-----------------------------------------------------------

We show that genetic *in vivo* overexpression of ZPR1 increases SMN protein levels and results in SMN-dependent improvements, including gross motor function, increase in overall growth, decrease in neurodegeneration and muscle atrophy, and increase in the lifespan of SMA mice. Together, these improvements show a systemic decrease in the severity of disease in SMA mice, which is conceptually in-line and consistent with findings that increase in SMN levels would result in amelioration of disease severity and the rescue of SMA phenotype. ZPR1 overexpression resulted in partial but systemic SMN-dependent rescue of SMA mice.

ZPR1 overexpression reduces severity of disease, increases lifespan and improves SMA phenotype. Comparison of survival of SMNΔ7 mice with other published studies shows broad range of average survival from ∼7 to 12 days reported in different studies with SMNΔ7 mouse model ([@awz373-B5]; [@awz373-B6]; [@awz373-B19]; [@awz373-B29]). The SMAΔ7 mice without Flag-ZPR1 (SMA) show an average survival of SMA (male and female) (7.07 ± 0.78, *n =* 26) days under our laboratory conditions and is consistent with our and others' findings ([@awz373-B19]; [@awz373-B29]). Z-SMA mice (littermates) show significant increase in average survival (17.93 ± 0.34, *P* \< 0.0001) days. The decrease in average survival of the original SMA line (4299) ([@awz373-B30]) from ∼10 to ∼7 days was stabilized in our laboratory and this might be because of several factors, including diet, local environment and genetic modifications such as addition of a transgene to create new strain. It is established that the changes in the genetic content of SMAΔ7 model causes alteration in phenotype, including average and max survival ([@awz373-B37]; [@awz373-B19]). To eliminate the possibility of genetic variation, we analysed and compared data from littermates produced by breeding of Z-SMA carrier strain (*Smn*^+/−^; *SMN2^+^*^/*+*^; *SMNΔ7^+^*^/*+*^; *Flag-Zpr1*^+/−^). The increase in the median (3-fold), average (2.53-fold) and maximum (9 days) survival time of Z-SMA mice compared to SMA mice suggests that ZPR1 overexpression markedly reduces severity of disease resulting in an increase of survival of Z-SMA mice. Notably, marked increase in the initial (15.5-fold) suggest minimization of variation in disease severity present in SMA mice that leads to striking increase in minimal survival after birth for at least 15 days in male and female Z-SMA mice. Gender-based analysis shows that ZPR1 improves phenotypes of male and female mice. The normal mouse lifespan of ∼8--9 days is equivalent to ∼1 year of human life ([@awz373-B10]); however, similar increases in lifespan under disease conditions may have a profound effect on the increase in lifespan of SMA patients and such correlation remains to be studied.

Our data show systemic partial rescue and the reasons for this may include moderate to low levels increase in SMN amount in different neuronal and non-neuronal tissues. Low level increases in SMN might be because of insufficient expression of the *Zpr1* gene under the control of mouse *Rosa26* promoter in liver and muscle tissues. Our data show that ∼3-fold increase in total ZPR1 levels in the spinal cord, brain, heart and lung tissues results in ∼3-fold increase in SMN levels suggesting a direct correlation between ZPR1 and SMN levels. Analysis of other tissues affected in SMA show a small increase in total ZPR1expression in liver (∼18%) that result in a very small and non-significant increase (∼5%) in SMN. SMN deficiency in liver has been shown to causes defects in liver development that result in late embryonic lethality in mice, suggesting that low levels of SMN in the liver may partially impair its function and contribute to severity during the course of disease progression ([@awz373-B54]). Skeletal muscle is the second most affected tissue in SMA and downregulation of SMN in skeletal muscle results in severe muscle dystrophy, suggesting that the normal SMN levels are critical for maintenance and function of skeletal muscle ([@awz373-B7]). A small increase (∼7%) in SMN in muscle may be because of low level expression of *Rosa26* promoter in muscle tissue resulting in a non-significant increase (∼17%, *P* = 0.386) in ZPR1 levels that maybe insufficient for full rescue of skeletal muscle phenotype in Z-SMA. However, improvements found in skeletal muscle, including reduced degeneration and increase in myofibre size might be because of reduced neurodegeneration, which is consistent with previous findings that SMN-independent reduction in neurodegeneration improves muscle growth, strength and myofibre size in the SMAΔ7 model ([@awz373-B19]). Together, these findings suggest that restoration of SMN levels in the liver and muscle tissues maybe critical for full rescue of SMA disease phenotype.

The moderate improvement in the overall disease phenotype with modest increase in the median survival (3-fold) of Z-SMA mice compared to other reported splicing modifiers and gene therapy methods used in SMAΔ7 mice raise the possibility of contribution of unanticipated toxic and off target effects of ZPR1 overexpression ([@awz373-B48], [@awz373-B47]; [@awz373-B39]; [@awz373-B35]). The inflammation of genitals noted in males homozygous for the transgene (*Flag-Zpr1^+^*^/*+*^) compared to males heterozygous for the transgene (*Flag-Zpr1*^+/−^) indicates a possibility of a toxic effect of ZPR1 overexpression. However, the inflammation in homozygous males might not be because of the toxic effect of increased ZPR1 levels because females with the homozygous *Flag-Zpr1^+^*^/*+*^ genotype did not show any adverse effect, were fertile and lived the normal lifespan, suggesting undetectable or no toxicity on doubling of ZPR1 expression, and homozygous males did not show any other complication and lived a normal lifespan. Therefore, it is possible that inflammation in males might be due to the disruption of a non-essential gene, specific to male genitals, at the site of integration of transgene in the mouse genomic locus.

Our previous studies with stable and transient ZPR1 overexpression in single cell models (*Saccharomyces cerevisiae and S. pombe*) and mammalian cells did not show any detectable cellular toxicity ([@awz373-B13]; [@awz373-B17]; [@awz373-B2]). The probability of toxic or off target effects may be low because ZPR1 forms complexes with SMN and is required for translocation of SMN to the nucleus. Cells derived from SMA patients have very low levels of ZPR1-SMN complexes ([@awz373-B18]). Several studies have demonstrated that deficiency of either ZPR1 or SMN cause similar defects in mRNA splicing and transcription ([@awz373-B42]; [@awz373-B18]; [@awz373-B57]) leading to neurodegeneration mediated by the JNK signalling pathway involving neuron-specific isoform JNK3 ([@awz373-B19]; [@awz373-B26]) suggesting that ZPR1-SMN complexes might be involved in common cellular functions, including mRNA biogenesis. Therefore, the majority of ZPR1 may form protein-protein complexes with SMN that might be critical for restoring cellular functions of SMA cells.

ZPR1 is downregulated in SMA patients and SMA mice ([@awz373-B18]; [@awz373-B23]; [@awz373-B2]). Upregulation of SMN levels by ZPR1 overexpression may help restore levels of critical molecular targets stemming downstream of SMN deficiency that are reported to be affected in SMA ([@awz373-B56]). Our data show that ZPR1 overexpression increases levels of two critical targets---SETX and DNA-PKcs---and rescues DNA damage, a leading cause of genomic instability and neurodegeneration in SMA ([@awz373-B27]). However, the effects of ZPR1 overexpression on systemic changes in the levels of potential ZPR1 targets, toxicity and off targets in Z-SMA mouse model remains to be examined. Moreover, the development of an actual therapeutic strategy for the treatment of SMA may utilize two different methods: (i) a pharmacological method using small compounds to upregulate the levels of ZPR1; and (ii) a gene therapy method using AAV9 vector to deliver AAV9-*ZPR1* intravenously. These therapeutic approaches will have their respective toxic or off target effects and will require preclinical studies to determine the efficacy and safety of drug compounds and gene therapy method before initiating human clinical trials.

Together, these data suggest that moderate increase in median survival (3-fold) of Z-SMA mice correlates with ∼3-fold increase in SMN levels by ZPR1, which may be equivalent to the amount of SMN produced by about three copies of *SMN2* in humans that may lead to moderate reduction in severity and amelioration of disease phenotype from severe (type I) to moderate (type II) in SMA patients. However, ZPR1-dependent rescue may not represent the best stand-alone strategy for the treatment of severe SMA (type I) but could be very useful in a combination therapy. Nevertheless, our data suggest that similar increase in ZPR1 expression in moderate SMA (type II) and mild SMA (type III and IV) patients that have higher *SMN2* copy numbers may show profound improvements with amelioration of type II to types III or IV phenotypes, and the rescue of types III and IV to the normal phenotype. In conclusion, this study shows ZPR1 is a transcriptional regulator of *SMN2* gene and an SMN-dependent protective modifier of SMA. ZPR1 represents a viable therapeutic target for developing a new method for the treatment of SMA.

Supplementary Material
======================

###### 

Click here for additional data file.

We thank Dr Arthur Burghes of Ohio State University for plasmids with human *SMN1* and *SMN2* promoters fused to luciferase. We thank Dr Olof Sundin, TTUHSC EP and Charlotte Sumner, John Hopkins Medical Institute, for reading and helpful comments on the manuscript. We thank graduate student Kabir Masih for assisting Dr Saif Ahmad with histological analysis and confocal microscopy.

Funding
=======

This study was supported by research grants to L.G. from the US National Institutes of Health (R01 NS064224), Cure SMA (GAN1920) and Muscular Dystrophy Association (MDA 480210).

Competing interests
===================

The authors report no competing interests.

See Hensel *et al.* (doi:10.1093/brain/awz394) for a scientific commentary on this article.

ChIP =

:   chromatin immunoprecipitation

DNA-PKcs =

:   DNA-activated protein kinase-catalytic subunit

GFP =

:   green fluorescent protein

NHEJ =

:   non-homologous end joining

NMJ =

:   neuromuscular junction

PND =

:   postnatal day

RNAPII =

:   RNA polymerase II

SMA =

:   spinal muscular atrophy

[^1]: Annapoorna Kannan and Xiaoting Jiang contributed equally to this work.
